BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sia D, Villanueva A, Friedman SL, Llovet JM. Liver Cancer Cell of Origin, Molecular Class, and Effects on Patient Prognosis. Gastroenterology. 2017;152:745-761. [PMID: 28043904 DOI: 10.1053/j.gastro.2016.11.048] [Cited by in Crossref: 373] [Cited by in F6Publishing: 376] [Article Influence: 62.2] [Reference Citation Analysis]
Number Citing Articles
1 Ali S, Haque N, Azhar Z, Saeinasab M, Sefat F. Regenerative Medicine of Liver: Promises, Advances and Challenges. Biomimetics (Basel) 2021;6:62. [PMID: 34698078 DOI: 10.3390/biomimetics6040062] [Reference Citation Analysis]
2 Chen K, Gorgen A, Ding A, Du L, Jiang K, Ding Y, Sapisochin G, Ghanekar A. Dual-Specificity Phosphatase 9 Regulates Cellular Proliferation and Predicts Recurrence After Surgery in Hepatocellular Carcinoma. Hepatol Commun 2021;5:1310-28. [PMID: 34278178 DOI: 10.1002/hep4.1701] [Reference Citation Analysis]
3 Sha M, Cao J, Sun HY, Tong Y, Xia Q. Neuroendocrine regulation of cholangiocarcinoma: A status quo review. Biochim Biophys Acta Rev Cancer 2019;1872:66-73. [PMID: 31152820 DOI: 10.1016/j.bbcan.2019.05.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
4 Kusano H, Naito Y, Mihara Y, Kondo R, Ogasawara S, Akiba J, Nakashima O, Yano H. Distinctive clinicopathological features and KRAS and IDH 1/2 mutation status of cholangiolocellular carcinoma. Hepatol Res 2019;50:84-91. [DOI: 10.1111/hepr.13428] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
5 Llovet JM, Montal R, Sia D, Finn RS. Molecular therapies and precision medicine for hepatocellular carcinoma. Nat Rev Clin Oncol. 2018;15:599-616. [PMID: 30061739 DOI: 10.1038/s41571-018-0073-4] [Cited by in Crossref: 482] [Cited by in F6Publishing: 494] [Article Influence: 160.7] [Reference Citation Analysis]
6 Dai Z, Wang X, Peng R, Zhang B, Han Q, Lin J, Wang J, Lin J, Jiang M, Liu H, Lee TH, Lu KP, Zheng M. Induction of IL-6Rα by ATF3 enhances IL-6 mediated sorafenib and regorafenib resistance in hepatocellular carcinoma. Cancer Lett 2022;524:161-71. [PMID: 34687791 DOI: 10.1016/j.canlet.2021.10.024] [Reference Citation Analysis]
7 Jiang HY, Chen J, Xia CC, Cao LK, Duan T, Song B. Noninvasive imaging of hepatocellular carcinoma: From diagnosis to prognosis. World J Gastroenterol 2018; 24(22): 2348-2362 [PMID: 29904242 DOI: 10.3748/wjg.v24.i22.2348] [Cited by in CrossRef: 47] [Cited by in F6Publishing: 37] [Article Influence: 11.8] [Reference Citation Analysis]
8 Ko S, Russell JO, Molina LM, Monga SP. Liver Progenitors and Adult Cell Plasticity in Hepatic Injury and Repair: Knowns and Unknowns. Annu Rev Pathol 2020;15:23-50. [PMID: 31399003 DOI: 10.1146/annurev-pathmechdis-012419-032824] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 6.7] [Reference Citation Analysis]
9 Vij M, Puri Y, Rammohan A, G G, Rajalingam R, Kaliamoorthy I, Rela M. Pathological, molecular, and clinical characteristics of cholangiocarcinoma: A comprehensive review. World J Gastrointest Oncol 2022; 14(3): 607-627 [DOI: 10.4251/wjgo.v14.i3.607] [Reference Citation Analysis]
10 Peng Y, Lin P, Wu L, Wan D, Zhao Y, Liang L, Ma X, Qin H, Liu Y, Li X, Wang X, He Y, Yang H. Ultrasound-Based Radiomics Analysis for Preoperatively Predicting Different Histopathological Subtypes of Primary Liver Cancer. Front Oncol 2020;10:1646. [PMID: 33072550 DOI: 10.3389/fonc.2020.01646] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
11 Ha K, Fujita M, Karlić R, Yang S, Xue R, Zhang C, Bai F, Zhang N, Hoshida Y, Polak P, Nakagawa H, Kim HG, Lee H. Somatic mutation landscape reveals differential variability of cell-of-origin for primary liver cancer. Heliyon 2020;6:e03350. [PMID: 32083210 DOI: 10.1016/j.heliyon.2020.e03350] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
12 Alison MR. The cellular origins of cancer with particular reference to the gastrointestinal tract. Int J Exp Pathol 2020;101:132-51. [PMID: 32794627 DOI: 10.1111/iep.12364] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
13 Chen J, Cao J, Wang P, He X. NT5DC2 is a novel prognostic marker in human hepatocellular carcinoma. Oncol Lett 2020;20:70. [PMID: 32863903 DOI: 10.3892/ol.2020.11931] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
14 Laschos K, Lampropoulou DI, Aravantinos G, Piperis M, Filippou D, Theodoropoulos G, Gazouli M. Exosomal noncoding RNAs in cholangiocarcinoma: Laboratory noise or hope? World J Gastrointest Surg 2020; 12(10): 407-424 [PMID: 33194090 DOI: 10.4240/wjgs.v12.i10.407] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
15 Sciarra A, Park YN, Sempoux C. Updates in the diagnosis of combined hepatocellular-cholangiocarcinoma. Human Pathology 2020;96:48-55. [DOI: 10.1016/j.humpath.2019.11.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
16 Castven D, Becker D, Czauderna C, Wilhelm D, Andersen JB, Strand S, Hartmann M, Heilmann‐heimbach S, Roth W, Hartmann N, Straub BK, Mahn FL, Franck S, Pereira S, Haupts A, Vogel A, Wörns MA, Weinmann A, Heinrich S, Lang H, Thorgeirsson SS, Galle PR, Marquardt JU. Application of patient‐derived liver cancer cells for phenotypic characterization and therapeutic target identification. Int J Cancer 2019;144:2782-94. [DOI: 10.1002/ijc.32026] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
17 Fang M, Zheng WJ, Yao M, Dong ZZ, Yao DF. Novel specific markers for hepatocellular carcinoma: Perspective on clinical applications. Shijie Huaren Xiaohua Zazhi 2017; 25(10): 865-873 [DOI: 10.11569/wcjd.v25.i10.865] [Cited by in CrossRef: 1] [Article Influence: 0.2] [Reference Citation Analysis]
18 Liang W, Liao Y, Li Z, Wang Y, Zheng S, Xu X, Ran F, Tang B, Wang Z. MicroRNA-644a promotes apoptosis of hepatocellular carcinoma cells by downregulating the expression of heat shock factor 1. Cell Commun Signal 2018;16:30. [PMID: 29898735 DOI: 10.1186/s12964-018-0244-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
19 Guo J, Deng N, Xu Y, Li L, Kuang D, Li M, Li X, Xu Z, Xiang M, Xu C. Bmi1 drives the formation and development of intrahepatic cholangiocarcinoma independent of Ink4A/Arf repression. Pharmacol Res 2021;164:105365. [PMID: 33307220 DOI: 10.1016/j.phrs.2020.105365] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Lin G, Sun W, Yang Z, Guo J, Liu H, Liang J. Hypoxia induces the expression of TET enzymes in HepG2 cells. Oncol Lett 2017;14:6457-62. [PMID: 29163682 DOI: 10.3892/ol.2017.7063] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
21 Ren F, Zhang J, Gao Z, Zhu H, Chen X, Liu W, Xue Z, Gao W, Wu R, Lv Y, Hu L. Racial disparities in the survival time of patients with hepatocellular carcinoma and intrahepatic cholangiocarcinoma between Chinese patients and patients of other racial groups: A population-based study from 2004 to 2013. Oncol Lett 2018;16:7102-16. [PMID: 30546445 DOI: 10.3892/ol.2018.9550] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
22 Wang YG, Wang T, Shi M, Zhai B. Long noncoding RNA EPB41L4A-AS2 inhibits hepatocellular carcinoma development by sponging miR-301a-5p and targeting FOXL1. J Exp Clin Cancer Res 2019;38:153. [PMID: 30971290 DOI: 10.1186/s13046-019-1128-9] [Cited by in Crossref: 34] [Cited by in F6Publishing: 44] [Article Influence: 11.3] [Reference Citation Analysis]
23 Chen Z, Liu L, Liu Y, Wang S, Zhang S, Dong R, Xu M, Ma Y, Wang J, Zhang Q, Wei P. Hydroxysafflor yellow A induces autophagy in human liver cancer cells by regulating Beclin 1 and ERK expression. Exp Ther Med 2020;19:2989-96. [PMID: 32256785 DOI: 10.3892/etm.2020.8552] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
24 Roy S, Ganguly N, Banerjee S. Exploring clinical implications and role of non-coding RNAs in lung carcinogenesis. Mol Biol Rep 2022. [PMID: 35076850 DOI: 10.1007/s11033-022-07159-w] [Reference Citation Analysis]
25 Ding WX, Sancho-Bru P. SOX9 acts downstream of YAP to decide liver cell fate and tumor types. J Hepatol 2021:S0168-8278(21)02250-9. [PMID: 34929213 DOI: 10.1016/j.jhep.2021.12.008] [Reference Citation Analysis]
26 Chen J, Rong X, Liu X, Zheng D, Rong X, Chen F, Zhao P, Liu F, Ruan J. FOXC2 is a prognostic biomarker and contributes to the growth and invasion of human hepatocellular carcinoma. Cancer Cell Int 2020;20:196. [PMID: 32508532 DOI: 10.1186/s12935-020-01265-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
27 Liu T, Shyh-Chang N. Oncofetal SALL4-Driven Tumorigenesis Is Highly Dependent on Oxidative Phosphorylation, Revealing Therapeutic Opportunities. Gastroenterology 2019;157:1475-7. [PMID: 31606470 DOI: 10.1053/j.gastro.2019.09.044] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
28 Nosaka T, Naito T, Hiramatsu K, Ohtani M, Nemoto T, Marusawa H, Ma N, Hiraku Y, Kawanishi S, Yamashita T, Kaneko S, Nakamoto Y. Gene expression profiling of hepatocarcinogenesis in a mouse model of chronic hepatitis B. PLoS One. 2017;12:e0185442. [PMID: 28968425 DOI: 10.1371/journal.pone.0185442] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
29 Pez F, Gifu P, Degli-Esposti D, Fares N, Lopez A, Lefrançois L, Michelet M, Rivoire M, Bancel B, Sylla BS, Herceg Z, Merle P, Caron de Fromentel C. In vitro transformation of primary human hepatocytes: Epigenetic changes and stemness properties. Exp Cell Res 2019;384:111643. [PMID: 31557464 DOI: 10.1016/j.yexcr.2019.111643] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
30 Natu A, Singh A, Gupta S. Hepatocellular carcinoma: Understanding molecular mechanisms for defining potential clinical modalities. World J Hepatol 2021; 13(11): 1568-1583 [PMID: 34904030 DOI: 10.4254/wjh.v13.i11.1568] [Reference Citation Analysis]
31 Zhang X, Tao X, Feng F. Downregulation of C12orf75 gene inhibits migration and invasion of liver cancer cell via suppressing the Wnt/β-catenin signaling pathway in vitro. Biochemical and Biophysical Research Communications 2022;614:92-9. [DOI: 10.1016/j.bbrc.2022.05.018] [Reference Citation Analysis]
32 Barcena-Varela M, Lujambio A. The Endless Sources of Hepatocellular Carcinoma Heterogeneity. Cancers (Basel) 2021;13:2621. [PMID: 34073538 DOI: 10.3390/cancers13112621] [Reference Citation Analysis]
33 He L, Fan X, Li Y, Chen M, Cui B, Chen G, Dai Y, Zhou D, Hu X, Lin H. Overexpression of zinc finger protein 384 (ZNF 384), a poor prognostic predictor, promotes cell growth by upregulating the expression of Cyclin D1 in Hepatocellular carcinoma. Cell Death Dis 2019;10:444. [PMID: 31168049 DOI: 10.1038/s41419-019-1681-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
34 Damrauer JS, Smith MA, Walter V, Thennavan A, Mose LE, Selitsky SR, Hoadley KA. Genomic characterization of rare molecular subclasses of hepatocellular carcinoma. Commun Biol 2021;4:1150. [PMID: 34608257 DOI: 10.1038/s42003-021-02674-1] [Reference Citation Analysis]
35 Wang C, Jiang X, Huang B, Zhou W, Cui X, Zheng C, Liu F, Bi J, Zhang Y, Luo H, Yuan L, Yang J, Yu Y. Inhibition of matrix stiffness relating integrin β1 signaling pathway inhibits tumor growth in vitro and in hepatocellular cancer xenografts. BMC Cancer 2021;21:1276. [PMID: 34823500 DOI: 10.1186/s12885-021-08982-3] [Reference Citation Analysis]
36 Zhou S, Liu G, Wu S. Marine bacterial surfactin CS30-2 induced necrosis-like cell death in Huh7.5 liver cancer cells. J Ocean Limnol 2020;38:826-33. [DOI: 10.1007/s00343-019-9129-2] [Reference Citation Analysis]
37 Calaf GM, Crispin LA, Muñoz JP, Aguayo F, Bleak TC. Muscarinic Receptors Associated with Cancer. Cancers 2022;14:2322. [DOI: 10.3390/cancers14092322] [Reference Citation Analysis]
38 Jia W, Liang S, Cheng B, Ling C. The Role of Cancer-Associated Fibroblasts in Hepatocellular Carcinoma and the Value of Traditional Chinese Medicine Treatment. Front Oncol 2021;11:763519. [PMID: 34868982 DOI: 10.3389/fonc.2021.763519] [Reference Citation Analysis]
39 Erice O, Vallejo A, Ponz-Sarvise M, Saborowski M, Vogel A, Calvisi DF, Saborowski A, Vicent S. Genetic Mouse Models as In Vivo Tools for Cholangiocarcinoma Research. Cancers (Basel) 2019;11:E1868. [PMID: 31769429 DOI: 10.3390/cancers11121868] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
40 Ekstrand C, Bahmanyar S, Cherif H, Kieler H, Linder M. Cancer risk in patients with primary immune thrombocytopenia - A Swedish nationwide register study. Cancer Epidemiol 2020;69:101806. [PMID: 32947155 DOI: 10.1016/j.canep.2020.101806] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
41 Zhang M, Wang D, Liu H, Li H. Tenofovir decrease hepatocellular carcinoma recurrence in chronic hepatitis B patients after liver resection. Infect Agent Cancer 2018;13:19. [PMID: 29977330 DOI: 10.1186/s13027-018-0191-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
42 Sengupta S, Parikh ND. Biomarker development for hepatocellular carcinoma early detection: Current and future perspectives. Hepat Oncol. 2017;4:111-122. [PMID: 30191058 DOI: 10.2217/hep-2017-0019] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 6.8] [Reference Citation Analysis]
43 Zanconato F, Cordenonsi M, Piccolo S. YAP and TAZ: a signalling hub of the tumour microenvironment. Nat Rev Cancer 2019;19:454-64. [PMID: 31270418 DOI: 10.1038/s41568-019-0168-y] [Cited by in Crossref: 110] [Cited by in F6Publishing: 100] [Article Influence: 36.7] [Reference Citation Analysis]
44 Yu P, Wu R, Zhou Z, Zhang X, Wang R, Wang X, Lin S, Wang J, Lv L. rAj-Tspin, a novel recombinant peptide from Apostichopus japonicus, suppresses the proliferation, migration, and invasion of BEL-7402 cells via a mechanism associated with the ITGB1-FAK-AKT pathway. Invest New Drugs 2021;39:377-85. [DOI: 10.1007/s10637-020-01008-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
45 Li L, Zhang W, Zhao S, Sun M. FOS-like antigen 1 is a prognostic biomarker in hepatocellular carcinoma. Saudi J Gastroenterol 2019;25:369-76. [PMID: 31274473 DOI: 10.4103/sjg.SJG_595_18] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
46 Schneller D, Angel P; Division of Signal Transduction and Growth Control, DKFZ-ZMBH Alliance, German Cancer Research Center (DKFZ), Heidelberg, Germany, Division of Signal Transduction and Growth Control, DKFZ-ZMBH Alliance, German Cancer Research Center (DKFZ), Heidelberg, Germany. Cellular Origin of Hepatocellular Carcinoma. In: Tirnitz-parker JE, editor. Hepatocellular Carcinoma. Codon Publications; 2019. pp. 1-28. [DOI: 10.15586/hepatocellularcarcinoma.2019.ch1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
47 Wang D, Zhang Q, Li F, Wang C, Yang C, Yu H. β-TrCP-mediated ubiquitination and degradation of Dlg5 regulates hepatocellular carcinoma cell proliferation. Cancer Cell Int 2019;19:298. [PMID: 31787846 DOI: 10.1186/s12935-019-1029-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
48 Wang X, He S, Zheng X, Huang S, Chen H, Chen H, Luo W, Guo Z, He X, Zhao Q. Transcriptional analysis of the expression, prognostic value and immune infiltration activities of the COMMD protein family in hepatocellular carcinoma. BMC Cancer 2021;21:1001. [PMID: 34493238 DOI: 10.1186/s12885-021-08699-3] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
49 Gingold JA, Zhu D, Lee DF, Kaseb A, Chen J. Genomic Profiling and Metabolic Homeostasis in Primary Liver Cancers. Trends Mol Med. 2018;24:395-411. [PMID: 29530485 DOI: 10.1016/j.molmed.2018.02.006] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 7.0] [Reference Citation Analysis]
50 Zhao C, Shi Q, Li H, Cui X, Xi Y, Cao Y, Xiang Z, Li F, Sun J, Liu J, Li T, Wei W, Xiong B, Li Z. Shape Designed Implanted Drug Delivery System for In Situ Hepatocellular Carcinoma Therapy. ACS Nano 2022. [PMID: 35549172 DOI: 10.1021/acsnano.2c03768] [Reference Citation Analysis]
51 Personeni N, Pressiani T, Bozzarelli S, Rimassa L. Targeted agents for second-line treatment of advanced hepatocellular carcinoma. World J Gastrointest Oncol 2019; 11(10): 788-803 [PMID: 31662820 DOI: 10.4251/wjgo.v11.i10.788] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
52 Al-Wahaibi LH, Al-Saleem MSM, Ahmed OAA, Fahmy UA, Alhakamy NA, Eid BG, Abdel-Naim AB, Abdel-Mageed WM, AlRasheed MM, Shazly GA. Optimized Conjugation of Fluvastatin to HIV-1 TAT Displays Enhanced Pro-Apoptotic Activity in HepG2 Cells. Int J Mol Sci 2020;21:E4138. [PMID: 32531976 DOI: 10.3390/ijms21114138] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
53 Bi YH, Han WQ, Li RF, Wang YJ, Du ZS, Wang XJ, Jiang Y. Signal transducer and activator of transcription 3 promotes the Warburg effect possibly by inducing pyruvate kinase M2 phosphorylation in liver precancerous lesions. World J Gastroenterol 2019; 25(16): 1936-1949 [PMID: 31086462 DOI: 10.3748/wjg.v25.i16.1936] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
54 Chen Y, Zhong W, Chen B, Yang C, Zhou S, Liu J. Effect of curcumin on vascular endothelial growth factor in hypoxic HepG2 cells via the insulin-like growth factor 1 receptor signaling pathway. Exp Ther Med 2018;15:2922-8. [PMID: 29599831 DOI: 10.3892/etm.2018.5783] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
55 Shen R, Ke L, Li Q, Dang X, Shen S, Shen J, Li S, Liang L, Peng B, Kuang M, Ma Y, Yang Z, Hua Y. Abnormal bile acid-microbiota crosstalk promotes the development of hepatocellular carcinoma. Hepatol Int 2022. [PMID: 35211843 DOI: 10.1007/s12072-022-10299-7] [Reference Citation Analysis]
56 Sharma R. Descriptive epidemiology of incidence and mortality of primary liver cancer in 185 countries: evidence from GLOBOCAN 2018. Jpn J Clin Oncol 2020;50:1370-9. [PMID: 32719873 DOI: 10.1093/jjco/hyaa130] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
57 Li X, Ramadori P, Pfister D, Seehawer M, Zender L, Heikenwalder M. The immunological and metabolic landscape in primary and metastatic liver cancer. Nat Rev Cancer 2021;21:541-57. [PMID: 34326518 DOI: 10.1038/s41568-021-00383-9] [Reference Citation Analysis]
58 Gurakar A, Ma M, Garonzik-wang J, Kim A, Anders RA, Oshima K, Georgiades C, Gurakar M, Ottmann S, Cameron AM, Philosophe B, Saberi B. Clinicopathological Distinction of Low-AFP-Secreting vs. High-AFP-Secreting Hepatocellular Carcinomas. Annals of Hepatology 2018;17:1052-66. [DOI: 10.5604/01.3001.0012.7206] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
59 Li M, Wang L, Wang Y, Zhang S, Zhou G, Lieshout R, Ma B, Liu J, Qu C, Verstegen MMA, Sprengers D, Kwekkeboom J, van der Laan LJW, Cao W, Peppelenbosch MP, Pan Q. Mitochondrial Fusion Via OPA1 and MFN1 Supports Liver Tumor Cell Metabolism and Growth. Cells 2020;9:E121. [PMID: 31947947 DOI: 10.3390/cells9010121] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 8.5] [Reference Citation Analysis]
60 Jia Y, Jin H, Gao L, Yang X, Wang F, Ding H, Chen A, Tan S, Zhang F, Shao J, Wang S, Zheng S. A novel lncRNA PLK4 up-regulated by talazoparib represses hepatocellular carcinoma progression by promoting YAP-mediated cell senescence. J Cell Mol Med 2020;24:5304-16. [PMID: 32243714 DOI: 10.1111/jcmm.15186] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
61 An Z, He P, Wang G, Liu G, Jiang J. PP-10 induces apoptosis via JNK/SPAK activation and STAT3 inhibition in Hepatocarcinoma cells in vitro. Food Sci Technol. [DOI: 10.1590/fst.102921] [Reference Citation Analysis]
62 Zhao N, Liu X, Guo H, Zhao X, Qiu Y, Wang W. Interleukin-35: An emerging player in the progression of liver diseases. Clin Res Hepatol Gastroenterol 2021;45:101518. [PMID: 33387857 DOI: 10.1016/j.clinre.2020.07.023] [Reference Citation Analysis]
63 Marcus R, Ferri-Borgogno S, Hosein A, Foo WC, Ghosh B, Zhao J, Rajapakshe K, Brugarolas J, Maitra A, Gupta S. Oncogenic KRAS Requires Complete Loss of BAP1 Function for Development of Murine Intrahepatic Cholangiocarcinoma. Cancers (Basel) 2021;13:5709. [PMID: 34830866 DOI: 10.3390/cancers13225709] [Reference Citation Analysis]
64 Bai Y, Tong W, Xie F, Zhu L, Wu H, Shi R, Wang L, Yang L, Liu Z, Miao F, Zhao Q, Zhang Y. DNA methylation biomarkers for diagnosis of primary liver cancer and distinguishing hepatocellular carcinoma from intrahepatic cholangiocarcinoma. Aging (Albany NY) 2021;13:17592-606. [PMID: 34237708 DOI: 10.18632/aging.203249] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
65 Zhou R, Wu K, Su M, Li R. Bioinformatic and experimental data decipher the pharmacological targets and mechanisms of plumbagin against hepatocellular carcinoma. Environmental Toxicology and Pharmacology 2019;70:103200. [DOI: 10.1016/j.etap.2019.103200] [Cited by in Crossref: 29] [Cited by in F6Publishing: 33] [Article Influence: 9.7] [Reference Citation Analysis]
66 Cao W, Liu X, Zhang Y, Li A, Xie Y, Zhou S, Song L, Xu R, Ma Y, Cai S, Tang X. BEZ235 Increases the Sensitivity of Hepatocellular Carcinoma to Sorafenib by Inhibiting PI3K/AKT/mTOR and Inducing Autophagy. Biomed Res Int 2021;2021:5556306. [PMID: 33987439 DOI: 10.1155/2021/5556306] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
67 Zhang L, Hu J, Hao M, Bu L. Long noncoding RNA Linc01296 promotes hepatocellular carcinoma development through regulation of the miR-26a/PTEN axis. Biol Chem 2020;401:407-16. [PMID: 31318685 DOI: 10.1515/hsz-2019-0231] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
68 Du B, Zhang P, Tan Z, Xu J. MiR-1202 suppresses hepatocellular carcinoma cells migration and invasion by targeting cyclin dependent kinase 14. Biomed Pharmacother 2017;96:1246-52. [PMID: 29217161 DOI: 10.1016/j.biopha.2017.11.090] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
69 Zhang Y, Zeng F, Han X, Weng J, Gao Y. Lineage tracing: technology tool for exploring the development, regeneration, and disease of the digestive system. Stem Cell Res Ther 2020;11:438. [PMID: 33059752 DOI: 10.1186/s13287-020-01941-y] [Reference Citation Analysis]
70 Wang K, Duan C, Zou X, Song Y, Li W, Xiao L, Peng J, Yao L, Long Q, Liu L. Increased mediator complex subunit 15 expression is associated with poor prognosis in hepatocellular carcinoma. Oncol Lett 2018;15:4303-13. [PMID: 29556287 DOI: 10.3892/ol.2018.7820] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
71 Mdlovu NB, Lin K, Weng M, Mdlovu NV. Formulation and in-vitro evaluations of doxorubicin loaded polymerized magnetic nanocarriers for liver cancer cells. Journal of the Taiwan Institute of Chemical Engineers 2021;126:278-87. [DOI: 10.1016/j.jtice.2021.06.059] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
72 Zhu J, Yu H, Chen S, Yang P, Dong Z, Ling Y, Tang H, Bai S, Yang W, Tang L, Shen F, Wang H, Wen W. Prognostic significance of combining high mobility group Box-1 and OV-6 expression in hepatocellular carcinoma. Sci China Life Sci 2018;61:912-23. [PMID: 29441453 DOI: 10.1007/s11427-017-9188-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
73 Cao H, Chen X, Wang Z, Wang L, Xia Q, Zhang W. The role of MDM2-p53 axis dysfunction in the hepatocellular carcinoma transformation. Cell Death Discov 2020;6:53. [PMID: 32595984 DOI: 10.1038/s41420-020-0287-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
74 Wu Q, Jiang S, Cheng T, Xu M, Lu B. A Novel Pyroptosis-related Prognostic Model for Hepatocellular Carcinoma. Front Cell Dev Biol 2021;9:770301. [PMID: 34869364 DOI: 10.3389/fcell.2021.770301] [Reference Citation Analysis]
75 Zhu X, Wang Z, Qiu X, Wang W, Bei C, Tan C, Qin L, Ren Y, Tan S. Rs2303428 of MSH2 Is Associated with Hepatocellular Carcinoma Prognosis in a Chinese Population. DNA Cell Biol 2018;37:634-41. [PMID: 29874113 DOI: 10.1089/dna.2018.4224] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
76 Hou JY, Wu HY, He RQ, Lin P, Dang YW, Chen G. Clinical and prognostic value of chaperonin containing T-complex 1 subunit 3 in hepatocellular carcinoma: A Study based on microarray and RNA-sequencing with 4272 cases. Pathol Res Pract 2019;215:177-94. [PMID: 30473171 DOI: 10.1016/j.prp.2018.11.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
77 Shi S, Verstegen MMA, Mezzanotte L, de Jonge J, Löwik CWGM, van der Laan LJW. Necroptotic Cell Death in Liver Transplantation and Underlying Diseases: Mechanisms and Clinical Perspective. Liver Transpl 2019;25:1091-104. [PMID: 31077562 DOI: 10.1002/lt.25488] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
78 Zhou T, Li S, Xiang D, Liu J, Sun W, Cui X, Ning B, Li X, Cheng Z, Jiang W, Zhang C, Liang X, Li L, Cheng X, Hui L, Wang H, Ding J. m6A RNA methylation-mediated HNF3γ reduction renders hepatocellular carcinoma dedifferentiation and sorafenib resistance. Signal Transduct Target Ther 2020;5:296. [PMID: 33361765 DOI: 10.1038/s41392-020-00299-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
79 Liu S, Zhou Z, Jia Y, Xue J, Liu Z, Cheng K, Cheng S, Liu S. Identification of portal vein tumor thrombus with an independent clonal origin in hepatocellular carcinoma via multi-omics data analysis. Cancer Biol Med 2019;16:147-70. [PMID: 31119055 DOI: 10.20892/j.issn.2095-3941.2018.0184] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
80 Chen Y, Yang YC, Zhu BL, Wu CC, Lin RF, Zhang X. Association between periodontal disease, tooth loss and liver diseases risk. J Clin Periodontol 2020;47:1053-63. [PMID: 32621350 DOI: 10.1111/jcpe.13341] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
81 Wang D, Zhang X, Lu Y, Wang X, Zhu L. Hypoxia inducible factor 1α in hepatocellular carcinoma with cirrhosis: Association with prognosis. Pathology - Research and Practice 2018;214:1987-92. [DOI: 10.1016/j.prp.2018.09.007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
82 Kim TH, Kim SG. Role of CXCR6 in Antitumor Immune Surveillance. Gastroenterology 2019;156:1565-8. [DOI: 10.1053/j.gastro.2019.03.032] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
83 Shi L, Yan P, Liang Y, Sun Y, Shen J, Zhou S, Lin H, Liang X, Cai X. Circular RNA expression is suppressed by androgen receptor (AR)-regulated adenosine deaminase that acts on RNA (ADAR1) in human hepatocellular carcinoma. Cell Death Dis 2017;8:e3171. [PMID: 29144509 DOI: 10.1038/cddis.2017.556] [Cited by in Crossref: 63] [Cited by in F6Publishing: 70] [Article Influence: 12.6] [Reference Citation Analysis]
84 Ito T. Editorial: impact of the introduction of direct-acting anti-viral drugs on hepatocarcinogenesis-a prospective serial follow-up MRI study. Aliment Pharmacol Ther 2020;52:735-6. [PMID: 32886380 DOI: 10.1111/apt.15911] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
85 Mcmillan RR, Saharia A, Abdelrahim M, Ghobrial RM. New Breakthroughs for Liver Transplantation of Cholangiocarcinoma. Curr Transpl Rep 2021;8:21-7. [DOI: 10.1007/s40472-021-00313-6] [Reference Citation Analysis]
86 Landerer S, Kalthoff S, Paulusch S, Strassburg CP. UDP-glucuronosyltransferase polymorphisms affect diethylnitrosamine-induced carcinogenesis in humanized transgenic mice. Cancer Sci 2020;111:4266-75. [PMID: 32860300 DOI: 10.1111/cas.14635] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
87 Nie H, Wang Y, Yang X, Liao Z, He X, Zhou J, Ou C. Clinical Significance and Integrative Analysis of the SMC Family in Hepatocellular Carcinoma. Front Med (Lausanne) 2021;8:727965. [PMID: 34527684 DOI: 10.3389/fmed.2021.727965] [Reference Citation Analysis]
88 Sirica AE, Strazzabosco M, Cadamuro M. Intrahepatic cholangiocarcinoma: Morpho-molecular pathology, tumor reactive microenvironment, and malignant progression. Adv Cancer Res 2021;149:321-87. [PMID: 33579427 DOI: 10.1016/bs.acr.2020.10.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
89 Montal R, Sia D, Montironi C, Leow WQ, Esteban-Fabró R, Pinyol R, Torres-Martin M, Bassaganyas L, Moeini A, Peix J, Cabellos L, Maeda M, Villacorta-Martin C, Tabrizian P, Rodriguez-Carunchio L, Castellano G, Sempoux C, Minguez B, Pawlik TM, Labgaa I, Roberts LR, Sole M, Fiel MI, Thung S, Fuster J, Roayaie S, Villanueva A, Schwartz M, Llovet JM. Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma. J Hepatol 2020;73:315-27. [PMID: 32173382 DOI: 10.1016/j.jhep.2020.03.008] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 14.5] [Reference Citation Analysis]
90 Martínez-Chantar ML, Avila MA, Lu SC. Hepatocellular Carcinoma: Updates in Pathogenesis, Detection and Treatment. Cancers (Basel) 2020;12:E2729. [PMID: 32977536 DOI: 10.3390/cancers12102729] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
91 Sun J, Chen Q, Ma J. Notch–Sox9 Axis Mediates Hepatocyte Dedifferentiation in KrasG12V-Induced Zebrafish Hepatocellular Carcinoma. IJMS 2022;23:4705. [DOI: 10.3390/ijms23094705] [Reference Citation Analysis]
92 Xu Z, Yan S, Wu H, Zhang Y, Wei W. Angiotensin II and tumor necrosis factor-α stimulate the growth, migration and invasion of BEL-7402 cells via down-regulation of GRK2 expression. Digestive and Liver Disease 2019;51:263-74. [DOI: 10.1016/j.dld.2018.06.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
93 Ruman U, Fakurazi S, Masarudin MJ, Hussein MZ. Nanocarrier-Based Therapeutics and Theranostics Drug Delivery Systems for Next Generation of Liver Cancer Nanodrug Modalities. Int J Nanomedicine 2020;15:1437-56. [PMID: 32184597 DOI: 10.2147/IJN.S236927] [Cited by in Crossref: 18] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
94 Shen Y, Li X, Su Y, Badshah SA, Zhang B, Xue Y, Shang P. HAMP Downregulation Contributes to Aggressive Hepatocellular Carcinoma via Mechanism Mediated by Cyclin4-Dependent Kinase-1/STAT3 Pathway. Diagnostics (Basel) 2019;9:E48. [PMID: 31052210 DOI: 10.3390/diagnostics9020048] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
95 Wang A, Jiang H, Liu Y, Chen J, Zhou X, Zhao C, Chen X, Lin M. Rhein induces liver cancer cells apoptosis via activating ROS-dependent JNK/Jun/caspase-3 signaling pathway. J Cancer. 2020;11:500-507. [PMID: 31897245 DOI: 10.7150/jca.30381] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
96 Mhlanga P, Perumal PO, Somboro AM, Amoako DG, Khumalo HM, Khan RB. Mechanistic Insights into Oxidative Stress and Apoptosis Mediated by Tannic Acid in Human Liver Hepatocellular Carcinoma Cells. Int J Mol Sci 2019;20:E6145. [PMID: 31817549 DOI: 10.3390/ijms20246145] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
97 Zhang C, Liu J, Han Z, Cui X, Peng D, Xing Y. Inhibition of TMEM16A suppresses growth and induces apoptosis in hepatocellular carcinoma. Int J Clin Oncol 2020;25:1145-54. [PMID: 32240440 DOI: 10.1007/s10147-020-01653-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
98 Gao X, Wang Y, Li Y, Wang Y, Yan M, Sun H, Chen S, Pan X. Huganpian, a traditional chinese medicine, inhibits liver cancer growth in vitro and in vivo by inducing autophagy and cell cycle arrest. Biomed Pharmacother 2019;120:109469. [PMID: 31698319 DOI: 10.1016/j.biopha.2019.109469] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
99 Zhou S, Wei J, Wang Y, Liu X. Cisplatin resistance-associated circRNA_101237 serves as a prognostic biomarker in hepatocellular carcinoma. Exp Ther Med 2020;19:2733-40. [PMID: 32226487 DOI: 10.3892/etm.2020.8526] [Cited by in Crossref: 8] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
100 Cao Y, Zhang H. Recent advances in nano material-based application of liver neoplasms. Smart Materials in Medicine 2021;2:114-23. [DOI: 10.1016/j.smaim.2021.03.001] [Reference Citation Analysis]
101 Chen G, Wang Y, Zhao X, Xie XZ, Zhao JG, Deng T, Chen ZY, Chen HB, Tong YF, Yang Z, Ding XW, Guo PY, Yu HT, Wu LJ, Zhang SN, Zhu QD, Li JJ, Shan YF, Yu FX, Yu ZP, Xia JL. A positive feedback loop between Periostin and TGFβ1 induces and maintains the stemness of hepatocellular carcinoma cells via AP-2α activation. J Exp Clin Cancer Res 2021;40:218. [PMID: 34193219 DOI: 10.1186/s13046-021-02011-8] [Reference Citation Analysis]
102 Abd Elhameed AG, Helal MG, Said E, Salem HA. Saxagliptin defers thioacetamide-induced hepatocarcinogenesis in rats: A novel suppressive impact on Wnt/Hedgehog/Notch1 signaling. Environ Toxicol Pharmacol 2021;86:103668. [PMID: 33945853 DOI: 10.1016/j.etap.2021.103668] [Reference Citation Analysis]
103 Liao R, Zhang XD, Li GZ, Qin KL, Yan X. Comparison of transcatheter arterial chemoembolization with raltitrexed plus liposomal doxorubicin vs. tegafur plus pirarubicin for unresectable hepatocellular carcinoma. J Gastrointest Oncol 2020;11:747-59. [PMID: 32953158 DOI: 10.21037/jgo-20-59] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
104 He Y, Shi M, Wu X, Ma J, Ng KT, Xia Q, Zhu L, Fu PP, Man K, Tsui SK, Lin G. Mutational Signature Analysis Reveals Widespread Contribution of Pyrrolizidine Alkaloid Exposure to Human Liver Cancer. Hepatology 2021;74:264-80. [PMID: 33462832 DOI: 10.1002/hep.31723] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
105 Ji XW, Jiang Y, Wu H, Zhou P, Tan YT, Li HL, Zhang L, Zhao WS, Xia QH, Bray F, Xiang YB. Long-term liver cancer incidence and mortality trends in the Changning District of Shanghai, China. J Dig Dis 2020;21:230-6. [PMID: 32124559 DOI: 10.1111/1751-2980.12855] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
106 Ebeling Barbier C, Heindryckx F, Lennernäs H. Limitations and Possibilities of Transarterial Chemotherapeutic Treatment of Hepatocellular Carcinoma. Int J Mol Sci 2021;22:13051. [PMID: 34884853 DOI: 10.3390/ijms222313051] [Reference Citation Analysis]
107 Yang Y, Chen Q, Piao HY, Wang B, Zhu GQ, Chen EB, Xiao K, Zhou ZJ, Shi GM, Shi YH, Wu WZ, Fan J, Zhou J, Dai Z. HNRNPAB-regulated lncRNA-ELF209 inhibits the malignancy of hepatocellular carcinoma. Int J Cancer 2020;146:169-80. [PMID: 31090062 DOI: 10.1002/ijc.32409] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
108 Shi C, Cai Y, Li Y, Li Y, Hu N, Ma S, Hu S, Zhu P, Wang W, Zhou H. Yap promotes hepatocellular carcinoma metastasis and mobilization via governing cofilin/F-actin/lamellipodium axis by regulation of JNK/Bnip3/SERCA/CaMKII pathways. Redox Biol 2018;14:59-71. [PMID: 28869833 DOI: 10.1016/j.redox.2017.08.013] [Cited by in Crossref: 144] [Cited by in F6Publishing: 143] [Article Influence: 28.8] [Reference Citation Analysis]
109 Pan F, Lin XR, Hao LP, Chu XY, Wan HJ, Wang R. The Role of RNA Methyltransferase METTL3 in Hepatocellular Carcinoma: Results and Perspectives. Front Cell Dev Biol 2021;9:674919. [PMID: 34046411 DOI: 10.3389/fcell.2021.674919] [Reference Citation Analysis]
110 Liu Z, Ma H, Lai Z. Revealing the potential mechanism of Astragalus membranaceus improving prognosis of hepatocellular carcinoma by combining transcriptomics and network pharmacology. BMC Complement Med Ther 2021;21:263. [PMID: 34663301 DOI: 10.1186/s12906-021-03425-9] [Reference Citation Analysis]
111 Ye Y, Yu F, Li Z, Xie Y, Yu X. RNA binding protein serine/arginine splicing factor 1 promotes the proliferation, migration and invasion of hepatocellular carcinoma by interacting with RecQ protein-like 4 mRNA. Bioengineered 2021;12:6144-54. [PMID: 34486474 DOI: 10.1080/21655979.2021.1972785] [Reference Citation Analysis]
112 Zhao CL, Hui Y, Wang LJ, Yang D, Yakirevich E, Mangray S, Huang CK, Lu S. Alanine-glyoxylate aminotransferase 1 (AGXT1) is a novel marker for hepatocellular carcinomas. Hum Pathol 2018;80:76-81. [PMID: 29883780 DOI: 10.1016/j.humpath.2018.05.025] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
113 Lequoy M, Gigante E, Couty JP, Desbois-Mouthon C. Hepatocellular carcinoma in the context of non-alcoholic steatohepatitis (NASH): recent advances in the pathogenic mechanisms. Horm Mol Biol Clin Investig 2020;41:/j/hmbci. [PMID: 32112699 DOI: 10.1515/hmbci-2019-0044] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
114 Zeng Z, Lu Q, Liu Y, Zhao J, Zhang Q, Hu L, Shi Z, Tu Y, Xiao Z, Xu Q, Huang D. Effect of the Hypoxia Inducible Factor on Sorafenib Resistance of Hepatocellular Carcinoma. Front Oncol 2021;11:641522. [PMID: 34307125 DOI: 10.3389/fonc.2021.641522] [Reference Citation Analysis]
115 Cao J, Wu L, Lei X, Shi K, Shi L, Shi Y. Long non-coding RNA-based signature for predicting prognosis of hepatocellular carcinoma. Bioengineered 2021;12:673-81. [PMID: 33622186 DOI: 10.1080/21655979.2021.1878763] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
116 Fan W, Yang X, Huang F, Tong X, Zhu L, Wang S. Identification of CD206 as a potential biomarker of cancer stem-like cells and therapeutic agent in liver cancer. Oncol Lett 2019;18:3218-26. [PMID: 31452799 DOI: 10.3892/ol.2019.10673] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
117 Li C, Zhang W, Yang H, Xiang J, Wang X, Wang J. Integrative analysis of dysregulated lncRNA-associated ceRNA network reveals potential lncRNA biomarkers for human hepatocellular carcinoma. PeerJ 2020;8:e8758. [PMID: 32201648 DOI: 10.7717/peerj.8758] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
118 Shi X, Li Q, Wang Y. Impact of regulatory T cells on the prognosis of hepatocellular carcinoma: A protocol for systematic review and meta analysis. Medicine (Baltimore) 2021;100:e23957. [PMID: 33545975 DOI: 10.1097/MD.0000000000023957] [Reference Citation Analysis]
119 Guo Y, Liu B, Huang T, Qi X, Li S. HOTAIR modulates hepatocellular carcinoma progression by activating FUT8/core-fucosylated Hsp90/MUC1/STAT3 feedback loop via JAK1/STAT3 cascade. Digestive and Liver Disease 2022. [DOI: 10.1016/j.dld.2022.04.009] [Reference Citation Analysis]
120 Zhao Y, Xue C, Xie Z, Ouyang X, Li L. Comprehensive analysis of ubiquitin-specific protease 1 reveals its importance in hepatocellular carcinoma. Cell Prolif 2020;53:e12908. [PMID: 32951278 DOI: 10.1111/cpr.12908] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
121 Liang WF, Gong YX, Li HF, Sun FL, Li WL, Chen DQ, Xie DP, Ren CX, Guo XY, Wang ZY, Kwon T, Sun HN. Curcumin Activates ROS Signaling to Promote Pyroptosis in Hepatocellular Carcinoma HepG2 Cells. In Vivo 2021;35:249-57. [PMID: 33402471 DOI: 10.21873/invivo.12253] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
122 Lu J, Xie Z, Xiao Z, Zhu D. The expression and function of miR-622 in a variety of tumors. Biomed Pharmacother 2021;146:112544. [PMID: 34929578 DOI: 10.1016/j.biopha.2021.112544] [Reference Citation Analysis]
123 Hatano Y, Ideta T, Hirata A, Hatano K, Tomita H, Okada H, Shimizu M, Tanaka T, Hara A. Virus-Driven Carcinogenesis. Cancers (Basel) 2021;13:2625. [PMID: 34071792 DOI: 10.3390/cancers13112625] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
124 Cheng Y, Chen T, Chen J. Erzhu Jiedu decoction ameliorates liver precancerous lesions in a rat model of liver cancer. J Cancer 2020;11:7302-11. [PMID: 33193894 DOI: 10.7150/jca.49554] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
125 Xu D, Wang Y, Wu J, Lin S, Chen Y, Zheng J. Identification and clinical validation of EMT-associated prognostic features based on hepatocellular carcinoma. Cancer Cell Int 2021;21:621. [PMID: 34819088 DOI: 10.1186/s12935-021-02326-8] [Reference Citation Analysis]
126 Alqahtani A, Khan Z, Alloghbi A, Said Ahmed TS, Ashraf M, Hammouda DM. Hepatocellular Carcinoma: Molecular Mechanisms and Targeted Therapies. Medicina (Kaunas) 2019;55:E526. [PMID: 31450841 DOI: 10.3390/medicina55090526] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 10.0] [Reference Citation Analysis]
127 Yu XQ, Yan QL, Shen S, Cheng ZY, Huang XX, Yao GD, Song SJ. Chamaejasmenin E from Stellera chamaejasme induces apoptosis of hepatocellular carcinoma cells by targeting c-Met in vitro and in vivo. Bioorg Chem 2021;:105509. [PMID: 34844768 DOI: 10.1016/j.bioorg.2021.105509] [Reference Citation Analysis]
128 Gadaleta RM, Moschetta A. DARK AND BRIGHT SIDE OF TARGETING THE FIBROBLAST GROWTH FACTOR RECEPTOR 4 IN THE LIVER. J Hepatol 2021:S0168-8278(21)01958-9. [PMID: 34364916 DOI: 10.1016/j.jhep.2021.07.029] [Reference Citation Analysis]
129 Zhang Q, Su R, Shan C, Gao C, Wu P. Non-SMC Condensin I Complex, Subunit G (NCAPG) is a Novel Mitotic Gene Required for Hepatocellular Cancer Cell Proliferation and Migration. Oncol Res. 2018;26:269-276. [PMID: 29046167 DOI: 10.3727/096504017x15075967560980] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 7.0] [Reference Citation Analysis]
130 Chen W, Huang L, Liang J, Ye Y, Yu S, Zhang Y. Long noncoding RNA small nucleolar RNA host gene 15 deteriorates liver cancer via microRNA-18b-5p/LIM-only 4 axis. IUBMB Life 2021;73:349-61. [PMID: 33372376 DOI: 10.1002/iub.2431] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
131 Kumar S, Fayaz F, Pottoo FH, Bajaj S, Manchanda S, Bansal H. Nanophytomedicine Based Novel Therapeutic Strategies in Liver Cancer. CTMC 2020;20:1999-2024. [DOI: 10.2174/1568026619666191114113048] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
132 Zhang B, Jiang J, Wu P, Zou J, Le J, Lin J, Li C, Luo B, Zhang Y, Huang R, Shao J. A smart dual-drug nanosystem based on co-assembly of plant and food-derived natural products for synergistic HCC immunotherapy. Acta Pharm Sin B 2021;11:246-57. [PMID: 33532190 DOI: 10.1016/j.apsb.2020.07.026] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
133 Fu R, Yu F, Wu W, Liu J, Li J, Guo F, Xu L, Wang F, Cui X. Bufalin enhances the killing efficacy of NK cells against hepatocellular carcinoma by inhibiting MICA shedding. Int Immunopharmacol 2021;101:108195. [PMID: 34678691 DOI: 10.1016/j.intimp.2021.108195] [Reference Citation Analysis]
134 Chen SL, Lu SX, Liu LL, Wang CH, Yang X, Zhang ZY, Zhang HZ, Yun JP. eEF1A1 Overexpression Enhances Tumor Progression and Indicates Poor Prognosis in Hepatocellular Carcinoma. Transl Oncol 2018;11:125-31. [PMID: 29248802 DOI: 10.1016/j.tranon.2017.11.001] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
135 Zhu F, Wang BR, Zhu ZF, Wang SQ, Chai CX, Shang D, Li M. Photodynamic therapy: A next alternative treatment strategy for hepatocellular carcinoma? World J Gastrointest Surg 2021; 13(12): 1523-1535 [DOI: 10.4240/wjgs.v13.i12.1523] [Reference Citation Analysis]
136 Zhang K, Che S, Pan C, Su Z, Zheng S, Yang S, Zhang H, Li W, Wang W, Liu J. The SHH/Gli axis regulates CD90-mediated liver cancer stem cell function by activating the IL6/JAK2 pathway. J Cell Mol Med 2018;22:3679-90. [PMID: 29722127 DOI: 10.1111/jcmm.13651] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
137 Zhou M, Deng Y, Liu M, Liao L, Dai X, Guo C, Zhao X, He L, Peng C, Li Y. The pharmacological activity of berberine, a review for liver protection. Eur J Pharmacol 2021;890:173655. [PMID: 33068590 DOI: 10.1016/j.ejphar.2020.173655] [Reference Citation Analysis]
138 Lapitz A, Arbelaiz A, Olaizola P, Aranburu A, Bujanda L, Perugorria MJ, Banales JM. Extracellular Vesicles in Hepatobiliary Malignancies. Front Immunol 2018;9:2270. [PMID: 30369925 DOI: 10.3389/fimmu.2018.02270] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
139 Wang Q, Li X, Qian B, Hu K, Liu B. Fluorescence imaging in the surgical management of liver cancers: Current status and future perspectives. Asian J Surg 2021:S1015-9584(21)00567-4. [PMID: 34656410 DOI: 10.1016/j.asjsur.2021.08.063] [Reference Citation Analysis]
140 Han ME, Kim JY, Kim GH, Park SY, Kim YH, Oh SO. SAC3D1: a novel prognostic marker in hepatocellular carcinoma. Sci Rep 2018;8:15608. [PMID: 30353105 DOI: 10.1038/s41598-018-34129-9] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 6.5] [Reference Citation Analysis]
141 Lv D, Chen L, Du L, Zhou L, Tang H. Emerging Regulatory Mechanisms Involved in Liver Cancer Stem Cell Properties in Hepatocellular Carcinoma. Front Cell Dev Biol 2021;9:691410. [PMID: 34368140 DOI: 10.3389/fcell.2021.691410] [Reference Citation Analysis]
142 Zhang Y, Ge T, Xiang P, Zhou J, Tang S, Mao H, Tang Q. Tanshinone IIA Reverses Oxaliplatin Resistance In Human Colorectal Cancer Via Inhibition Of ERK/Akt Signaling Pathway. Onco Targets Ther 2019;12:9725-34. [PMID: 32009805 DOI: 10.2147/OTT.S217914] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
143 Li ZP, Tian GX, Jiang H, Pan RY, Lian B, Wang M, Gao ZQ, Zhang B, Wu JL. Liver-Targeting and pH-Sensitive Sulfated Hyaluronic Acid Mixed Micelles for Hepatoma Therapy. Int J Nanomedicine 2019;14:9437-52. [PMID: 31819442 DOI: 10.2147/IJN.S214528] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 3.7] [Reference Citation Analysis]
144 Shuai T, Zhou Y, Shao G, Yang R, Wang L, Wang J, Sun J, Ren L, Wang J, Liao Y, Wei M, Xu Q, Li Y, Zhao L. Bimodal Molecule as NIR-CT Contrast Agent for Hepatoma Specific Imaging. Anal Chem 2020;92:1138-46. [PMID: 31820637 DOI: 10.1021/acs.analchem.9b04212] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
145 Luo T, Zhang FX, Zhao K, Gao HY, Zhang SG, Wang L, Dou GF, Liu T, Yu M, Zhan YQ, Chen H, Yang XM, Li CY. Preclinical Pharmacokinetics, Tissue Distribution, and Primary Safety Evaluation of Indo5, a Novel Selective Inhibitor of c-Met and Trks. Front Pharmacol 2021;12:711126. [PMID: 34447310 DOI: 10.3389/fphar.2021.711126] [Reference Citation Analysis]
146 Kasprzak A, Adamek A. Mucins: the Old, the New and the Promising Factors in Hepatobiliary Carcinogenesis. Int J Mol Sci 2019;20:E1288. [PMID: 30875782 DOI: 10.3390/ijms20061288] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 8.7] [Reference Citation Analysis]
147 Castelli G, Pelosi E, Testa U. Liver Cancer: Molecular Characterization, Clonal Evolution and Cancer Stem Cells. Cancers (Basel) 2017;9:E127. [PMID: 28930164 DOI: 10.3390/cancers9090127] [Cited by in Crossref: 47] [Cited by in F6Publishing: 46] [Article Influence: 9.4] [Reference Citation Analysis]
148 Ye Z, He Q, Wang Q, Lin Y, Cen K, Chen X. LINC00922 promotes the proliferation, migration, invasion and EMT process of liver cancer cells by regulating miR-424-5p/ARK5. Mol Cell Biochem 2021;476:3757-69. [PMID: 34097192 DOI: 10.1007/s11010-021-04196-0] [Reference Citation Analysis]
149 Iscan E, Ekin U, Yildiz G, Oz O, Keles U, Suner A, Cakan-Akdogan G, Ozhan G, Nekulova M, Vojtesek B, Uzuner H, Karakülah G, Alotaibi H, Ozturk M. TAp73β Can Promote Hepatocellular Carcinoma Dedifferentiation. Cancers (Basel) 2021;13:783. [PMID: 33668566 DOI: 10.3390/cancers13040783] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
150 Ma Y, Zhang C, Zhang B, Yu H, Yu Q. circRNA of AR-suppressed PABPC1 91 bp enhances the cytotoxicity of natural killer cells against hepatocellular carcinoma via upregulating UL16 binding protein 1. Oncol Lett 2019;17:388-97. [PMID: 30655779 DOI: 10.3892/ol.2018.9606] [Cited by in Crossref: 10] [Cited by in F6Publishing: 21] [Article Influence: 2.5] [Reference Citation Analysis]
151 Zhao H, Bi M, Lou M, Yang X, Sun L. Downregulation of SOX2-OT Prevents Hepatocellular Carcinoma Progression Through miR-143-3p/MSI2. Front Oncol 2021;11:685912. [PMID: 34322386 DOI: 10.3389/fonc.2021.685912] [Reference Citation Analysis]
152 Xie X, Wang Y, Zhang S, Li J, Yu Z, Ding X, Ye L, Gong P, Zhu Q, Li J, Chen Z, Yao X, Du Z, Zeng Q, Chen H, Yang Z, Chen G. A novel five-lncRNA signature panel improves high-risk survival prediction in patients with cholangiocarcinoma. Aging (Albany NY) 2021;13:2959-81. [PMID: 33472169 DOI: 10.18632/aging.202446] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
153 Ji L, Tang Y, Pang X, Zhang Y. Increased Expression of Serine Hydroxymethyltransferase 2 (SHMT2) is a Negative Prognostic Marker in Patients with Hepatocellular Carcinoma and is Associated with Proliferation of HepG2 Cells. Med Sci Monit 2019;25:5823-32. [PMID: 31379360 DOI: 10.12659/MSM.915754] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
154 Zhu X, Feng Y, He D, Wang Z, Huang F, Tu J. Clinical Value and Underlying Mechanisms of Upregulated LINC00485 in Hepatocellular Carcinoma. Front Oncol 2021;11:654424. [PMID: 34290977 DOI: 10.3389/fonc.2021.654424] [Reference Citation Analysis]
155 Mohammed FA, Elkady AI, Syed FQ, Mirza MB, Hakeem KR, Alkarim S. Anethum graveolens (dill) – A medicinal herb induces apoptosis and cell cycle arrest in HepG2 cell line. Journal of Ethnopharmacology 2018;219:15-22. [DOI: 10.1016/j.jep.2018.03.008] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
156 Zhang P, Liu Q, Yuan M, Wang L. Tenofovir disoproxil fumarate reduce incidence of HCC development in CHB-patients with compensated cirrhosis. Infect Agent Cancer 2018;13:30. [PMID: 30181772 DOI: 10.1186/s13027-018-0203-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
157 Chen PP, Zhang ZS, Wu JC, Zheng JF, Lin F. LncRNA SNHG12 promotes proliferation and epithelial mesenchymal transition in hepatocellular carcinoma through targeting HEG1 via miR-516a-5p. Cell Signal 2021;84:109992. [PMID: 33774129 DOI: 10.1016/j.cellsig.2021.109992] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
158 Tai Y, Zhang LH, Gao JH, Zhao C, Tong H, Ye C, Huang ZY, Liu R, Tang CW. Suppressing growth and invasion of human hepatocellular carcinoma cells by celecoxib through inhibition of cyclooxygenase-2. Cancer Manag Res 2019;11:2831-48. [PMID: 31114336 DOI: 10.2147/CMAR.S183376] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 3.3] [Reference Citation Analysis]
159 Wang J, Pu J, Zhang Y, Yao T, Luo Z, Li W, Xu G, Liu J, Wei W, Deng Y. DANCR contributed to hepatocellular carcinoma malignancy via sponging miR-216a-5p and modulating KLF12. J Cell Physiol 2019;234:9408-16. [PMID: 30430564 DOI: 10.1002/jcp.27625] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 6.0] [Reference Citation Analysis]
160 Ali ES, Rychkov GY, Barritt GJ. Targeting Ca2+ Signaling in the Initiation, Promotion and Progression of Hepatocellular Carcinoma. Cancers (Basel) 2020;12:E2755. [PMID: 32987945 DOI: 10.3390/cancers12102755] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
161 Dai X, Wang S, Niu C, Ji B, Liu Y. Overview of Current Progress in Immune Checkpoint Inhibitor Therapy for Advanced Hepatocellular Carcinoma. Technol Cancer Res Treat 2020;19:153303382094748. [DOI: 10.1177/1533033820947486] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
162 Ji Q, Wang W, Luo Y, Cai F, Lu Y, Deng W, Li Q, Su S. Characteristic proteins in the plasma of postoperative colorectal and liver cancer patients with Yin deficiency of liver-kidney syndrome. Oncotarget 2017;8:103223-35. [PMID: 29262557 DOI: 10.18632/oncotarget.21735] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
163 Feng L, Wang Y, Wang X, An S, Aizimuaji Z, Tao C, Zhang K, Cheng S, Wu J, Xiao T, Rong W. Integrated analysis of the rhesus monkey liver transcriptome during development and human primary HCC AFP-related gene expression. Mol Ther Nucleic Acids 2021;25:406-15. [PMID: 34484865 DOI: 10.1016/j.omtn.2021.06.004] [Reference Citation Analysis]
164 Cast A, Valanejad L, Wright M, Nguyen P, Gupta A, Zhu L, Shin S, Timchenko N. C/EBPα-dependent preneoplastic tumor foci are the origin of hepatocellular carcinoma and aggressive pediatric liver cancer. Hepatology 2018;67:1857-71. [PMID: 29159818 DOI: 10.1002/hep.29677] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 5.8] [Reference Citation Analysis]
165 Jin Y, Yang R, Ding J, Zhu F, Zhu C, Xu Q, Cai J. KAT6A is associated with sorafenib resistance and contributes to progression of hepatocellular carcinoma by targeting YAP. Biochem Biophys Res Commun 2021;585:185-90. [PMID: 34808502 DOI: 10.1016/j.bbrc.2021.09.009] [Reference Citation Analysis]
166 Gringeri E, Gambato M, Sapisochin G, Ivanics T, Lynch EN, Mescoli C, Burra P, Cillo U, Russo FP. Cholangiocarcinoma as an Indication for Liver Transplantation in the Era of Transplant Oncology. J Clin Med 2020;9:E1353. [PMID: 32380750 DOI: 10.3390/jcm9051353] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
167 Ni JY, Liu SS, Sun HL, Wang WD, Zhong ZL, Hou SN, Chen YT, Xu LF. Transcatheter hepatic arterial infusion chemotherapy vs sorafenib in the treatment of patients with hepatocellular carcinoma of Barcelona Clinic Liver Cancer stage C: a meta-analysis of Asian population. Onco Targets Ther 2018;11:7883-94. [PMID: 30464535 DOI: 10.2147/OTT.S156844] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
168 Wang D, Ning Z, Zhu Z, Zhang C, Wang P, Meng Z. LHPP suppresses tumorigenesis of intrahepatic cholangiocarcinoma by inhibiting the TGFβ/smad signaling pathway. Int J Biochem Cell Biol 2021;132:105845. [PMID: 33401010 DOI: 10.1016/j.biocel.2020.105845] [Reference Citation Analysis]
169 He C, Jaffar Ali D, Li Y, Zhu Y, Sun B, Xiao Z. Engineering of HN3 increases the tumor targeting specificity of exosomes and upgrade the anti-tumor effect of sorafenib on HuH-7 cells. PeerJ 2020;8:e9524. [PMID: 33062407 DOI: 10.7717/peerj.9524] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
170 Reungoat E, Grigorov B, Zoulim F, Pécheur EI. Molecular Crosstalk between the Hepatitis C Virus and the Extracellular Matrix in Liver Fibrogenesis and Early Carcinogenesis. Cancers (Basel) 2021;13:2270. [PMID: 34065048 DOI: 10.3390/cancers13092270] [Reference Citation Analysis]
171 Uno S, Kataoka TR, Okajima H, Taura K, Sakurai T, Haga H. Perihilar cholangiocarcinoma in an explanted liver after Kasai operation for biliary atresia: A case report and literature review. Pathol Int 2020;70:888-92. [PMID: 32936992 DOI: 10.1111/pin.13016] [Reference Citation Analysis]
172 Kong FE, Li GM, Tang YQ, Xi SY, Loong JHC, Li MM, Li HL, Cheng W, Zhu WJ, Mo JQ, Gong YF, Tang H, Zhao Y, Zhang Y, Ma S, Guan XY, Ma NF, Xie MB, Liu M. Targeting tumor lineage plasticity in hepatocellular carcinoma using an anti-CLDN6 antibody-drug conjugate. Sci Transl Med 2021;13:eabb6282. [PMID: 33536280 DOI: 10.1126/scitranslmed.abb6282] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
173 Jiao Y, Wu Y, Du D. Polydatin inhibits cell proliferation, invasion and migration, and induces cell apoptosis in hepatocellular carcinoma. Braz J Med Biol Res 2018;51:e6867. [PMID: 29513792 DOI: 10.1590/1414-431X20176867] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
174 Xu J, Yan B, Zhang L, Zhou L, Zhang J, Yu W, Dong X, Yao L, Shan L. Theabrownin Induces Apoptosis and Tumor Inhibition of Hepatocellular Carcinoma Huh7 Cells Through ASK1-JNK-c-Jun Pathway. Onco Targets Ther 2020;13:8977-87. [PMID: 32982289 DOI: 10.2147/OTT.S254693] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
175 Guo J, Wang M, Wang JP, Wu CX. Ubiquitin-conjugating enzyme E2T knockdown suppresses hepatocellular tumorigenesis via inducing cell cycle arrest and apoptosis. World J Gastroenterol 2019; 25(43): 6386-6403 [PMID: 31798276 DOI: 10.3748/wjg.v25.i43.6386] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
176 Loft A, Alfaro AJ, Schmidt SF, Pedersen FB, Terkelsen MK, Puglia M, Chow KK, Feuchtinger A, Troullinaki M, Maida A, Wolff G, Sakurai M, Berutti R, Ekim Üstünel B, Nawroth P, Ravnskjaer K, Diaz MB, Blagoev B, Herzig S. Liver-fibrosis-activated transcriptional networks govern hepatocyte reprogramming and intra-hepatic communication. Cell Metab 2021;33:1685-1700.e9. [PMID: 34237252 DOI: 10.1016/j.cmet.2021.06.005] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
177 Qiu Y, Cao Y, Cao W, Jia Y, Lu N. The Application of Ferroptosis in Diseases. Pharmacological Research 2020;159:104919. [DOI: 10.1016/j.phrs.2020.104919] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 13.0] [Reference Citation Analysis]
178 Ogunwobi OO, Harricharran T, Huaman J, Galuza A, Odumuwagun O, Tan Y, Ma GX, Nguyen MT. Mechanisms of hepatocellular carcinoma progression. World J Gastroenterol 2019; 25(19): 2279-2293 [PMID: 31148900 DOI: 10.3748/wjg.v25.i19.2279] [Cited by in CrossRef: 47] [Cited by in F6Publishing: 44] [Article Influence: 15.7] [Reference Citation Analysis]
179 de Jong KP, Ruiter SJS, Pennings JP. Stereotactic image guided microwave ablation of HCC: A step forward and still a long way to go. Liver Int 2019;39:1798-800. [PMID: 31553528 DOI: 10.1111/liv.14238] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
180 Hasanzad M, Sarhangi N, Aghaei Meybodi HR, Nikfar S, Khatami F, Larijani B. Precision Medicine in Non Communicable Diseases. Int J Mol Cell Med 2019;8:1-18. [PMID: 32351905 DOI: 10.22088/IJMCM.BUMS.8.2.1] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
181 Zhang HF, Wang YC, Han YD. MicroRNA‑34a inhibits liver cancer cell growth by reprogramming glucose metabolism. Mol Med Rep 2018;17:4483-9. [PMID: 29328457 DOI: 10.3892/mmr.2018.8399] [Cited by in Crossref: 7] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
182 Zhao F, Feng G, Zhu J, Su Z, Guo R, Liu J, Zhang H, Zhai Y. 3-Methyladenine-enhanced susceptibility to sorafenib in hepatocellular carcinoma cells by inhibiting autophagy. Anticancer Drugs 2021;32:386-93. [PMID: 33395067 DOI: 10.1097/CAD.0000000000001032] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
183 Shi W, Feng L, Dong S, Ning Z, Hua Y, Liu L, Chen Z, Meng Z. FBXL6 governs c-MYC to promote hepatocellular carcinoma through ubiquitination and stabilization of HSP90AA1. Cell Commun Signal 2020;18:100. [PMID: 32576198 DOI: 10.1186/s12964-020-00604-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
184 Ganai SA, Sheikh FA, Baba ZA, Mir MA, Mantoo MA, Yatoo MA. Anticancer activity of the plant flavonoid luteolin against preclinical models of various cancers and insights on different signalling mechanisms modulated. Phytotherapy Research 2021;35:3509-32. [DOI: 10.1002/ptr.7044] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
185 Pastore M, Lori G, Gentilini A, Taddei ML, Di Maira G, Campani C, Recalcati S, Invernizzi P, Marra F, Raggi C. Multifaceted Aspects of Metabolic Plasticity in Human Cholangiocarcinoma: An Overview of Current Perspectives. Cells 2020;9:E596. [PMID: 32138158 DOI: 10.3390/cells9030596] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
186 Hong X, Luo H, Zhu G, Guan X, Jia Y, Yu H, Lv X, Yu T, Lan H, Zhang Q, Li H, Sun W, Huang X, Li J. SSR2 overexpression associates with tumorigenesis and metastasis of Hepatocellular Carcinoma through modulating EMT. J Cancer 2020;11:5578-87. [PMID: 32913453 DOI: 10.7150/jca.44788] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
187 Fazry S, Noordin MAM, Sanusi S, Noor MM, Aizat WM, Lazim AM, Dyari HRE, Jamar NH, Remali J, Othman BA, Law D, Sidik NM, Cheah YH, Lim YC. Cytotoxicity and Toxicity Evaluation of Xanthone Crude Extract on Hypoxic Human Hepatocellular Carcinoma and Zebrafish (Danio rerio) Embryos. Toxics 2018;6:E60. [PMID: 30304811 DOI: 10.3390/toxics6040060] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
188 Yan X, Liu L, Zhang Y, Song T, Liang Y, Liu Z, Bao X, Mao L, Qiu Y. Perioperative Enteral Nutrition Improves Postoperative Recovery for Patients with Primary Liver Cancer: A Randomized Controlled Clinical Trial. Nutr Cancer 2021;73:1924-32. [PMID: 32875913 DOI: 10.1080/01635581.2020.1814824] [Reference Citation Analysis]
189 Wu T, Jiang X, Zhang X, Wu B, Xu B, Liu X, Zheng L, Wang Y. Intrahepatic Cholangiocarcinoma: State of the Art of FGFR Inhibitors. Cancer Control 2021;28:1073274821989314. [PMID: 33618536 DOI: 10.1177/1073274821989314] [Reference Citation Analysis]
190 Wirtz TH, Saal A, Bergmann I, Fischer P, Heinrichs D, Brandt EF, Koenen MT, Djudjaj S, Schneider KM, Boor P, Bucala R, Weiskirchen R, Bernhagen J, Trautwein C, Berres ML. Macrophage migration inhibitory factor exerts pro-proliferative and anti-apoptotic effects via CD74 in murine hepatocellular carcinoma. Br J Pharmacol 2021. [PMID: 34250589 DOI: 10.1111/bph.15622] [Reference Citation Analysis]
191 Yuan B, Liu J, Cao J, Yu Y, Zhang H, Wang F, Zhu Y, Xiao M, Liu S, Ye Y, Ma L, Xu D, Xu N, Li Y, Zhao B, Xu P, Jin J, Xu J, Chen X, Shen L, Lin X, Feng XH. PTPN3 acts as a tumor suppressor and boosts TGF-β signaling independent of its phosphatase activity. EMBO J 2019;38:e99945. [PMID: 31304624 DOI: 10.15252/embj.201899945] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
192 Xu M, Wang J, Xu Z, Li R, Wang P, Shang R, Cigliano A, Ribback S, Solinas A, Pes GM, Evert K, Wang H, Song X, Zhang S, Che L, Pascale RM, Calvisi DF, Liu Q, Chen X. SNAI1 Promotes the Cholangiocellular Phenotype, but not Epithelial-Mesenchymal Transition, in a Murine Hepatocellular Carcinoma Model. Cancer Res 2019;79:5563-74. [PMID: 31383647 DOI: 10.1158/0008-5472.CAN-18-3750] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
193 Hasan MN, Choudhry H, Razvi SS, Moselhy SS, Kumosani TA, Zamzami MA, Omran Z, Halwani MA, Al-Babili S, Abualnaja KO, Al-Malki AL, Alhosin M, Asami T. Synthetic strigolactone analogues reveal anti-cancer activities on hepatocellular carcinoma cells. Bioorg Med Chem Lett 2018;28:1077-83. [PMID: 29456109 DOI: 10.1016/j.bmcl.2018.02.016] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
194 Lu H, Gao L, Lv J. Circ_0078710 promotes the development of liver cancer by upregulating TXNDC5 via miR-431-5p. Ann Hepatol 2021;27:100551. [PMID: 34606982 DOI: 10.1016/j.aohep.2021.100551] [Reference Citation Analysis]
195 Hu ZG, Zhang S, Chen YB, Cao W, Zhou ZY, Zhang JN, Gao G, He SQ. DTNA promotes HBV-induced hepatocellular carcinoma progression by activating STAT3 and regulating TGFβ1 and P53 signaling. Life Sci 2020;258:118029. [PMID: 32619495 DOI: 10.1016/j.lfs.2020.118029] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
196 Zhang AB, Zhang ZH, Zhang J, Lin BY, Geng L, Yang Z, Feng XN, Zheng SS. Lower mean platelet volume is a risk indicator of hepatocellular carcinoma recurrence following liver transplantation. Hepatobiliary Pancreat Dis Int 2019;18:223-7. [PMID: 31056483 DOI: 10.1016/j.hbpd.2019.04.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
197 Chen C, Liang QY, Chen HK, Wu PF, Feng ZY, Ma XM, Wu HR, Zhou GQ. DRAM1 regulates the migration and invasion of hepatoblastoma cells via autophagy-EMT pathway. Oncol Lett 2018;16:2427-33. [PMID: 30013633 DOI: 10.3892/ol.2018.8937] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
198 Wang Y, Wang Y, Wang S, Tong Y, Jin L, Zong H, Zheng R, Yang J, Zhang Z, Ouyang E, Zhou M, Zhang X. GIDB: a knowledge database for the automated curation and multidimensional analysis of molecular signatures in gastrointestinal cancer. Database (Oxford) 2019;2019:baz051. [PMID: 31089686 DOI: 10.1093/database/baz051] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
199 Zhu H, Zhou W, Wan Y, Ge K, Lu J, Jia C. Nanomedicine-mediated induction of immunogenic cell death and prevention of PD-L1 overexpression for enhanced hepatocellular carcinoma therapy. Cancer Nano 2020;11. [DOI: 10.1186/s12645-020-00072-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
200 Han SH, Choe J. Diverse molecular functions of m6A mRNA modification in cancer. Exp Mol Med 2020;52:738-49. [PMID: 32404927 DOI: 10.1038/s12276-020-0432-y] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 8.0] [Reference Citation Analysis]
201 Jiang Y, Zheng X, Jiao D, Chen P, Xu Y, Wei H, Qian Y. Peptidase inhibitor 15 as a novel blood diagnostic marker for cholangiocarcinoma. EBioMedicine 2019;40:422-31. [PMID: 30638862 DOI: 10.1016/j.ebiom.2018.12.063] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
202 Yang Q, Wang L, Liu J, Cao W, Pan Q, Li M. Targeting the complex I and III of mitochondrial electron transport chain as a potentially viable option in liver cancer management. Cell Death Discov 2021;7:293. [PMID: 34650055 DOI: 10.1038/s41420-021-00675-x] [Reference Citation Analysis]
203 Tanaka H, Horioka K, Hasebe T, Sawada K, Nakajima S, Konishi H, Isozaki S, Goto M, Fujii Y, Kamikokura Y, Ogawa K, Nishikawa Y. Treatment of hepatocellular carcinoma with autologous platelets encapsulating sorafenib or lenvatinib: A novel therapy exploiting tumor‐platelet interactions. Intl Journal of Cancer. [DOI: 10.1002/ijc.33915] [Reference Citation Analysis]
204 Glantzounis GK, Kyrochristos ID, Ziogas DE, Lykoudis EG, Roukos DH. Novel translational therapeutic strategy by sequencing primary liver cancer genomes. Future Oncology 2017;13:1049-52. [DOI: 10.2217/fon-2017-0087] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
205 Yao X, Liu C, Liu C, Xi W, Sun S, Gao Z. lncRNA SNHG7 sponges miR-425 to promote proliferation, migration, and invasion of hepatic carcinoma cells via Wnt/β-catenin/EMT signalling pathway. Cell Biochem Funct 2019;37:525-33. [PMID: 31478234 DOI: 10.1002/cbf.3429] [Cited by in Crossref: 9] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
206 Wu H, Wang C, Sun J, Sun L, Wan J, Wang S, Gu D, Yu C, Yang C, He J, Zhang Z, Lv Y, Wang H, Yao M, Qin W, Wang C, Jin H. Self-Assembled and Self-Monitored Sorafenib/Indocyanine Green Nanodrug with Synergistic Antitumor Activity Mediated by Hyperthermia and Reactive Oxygen Species-Induced Apoptosis. ACS Appl Mater Interfaces 2019;11:43996-4006. [DOI: 10.1021/acsami.9b18086] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
207 Yamazoe T, Mori T, Yoshio S, Kanto T. Hepatocyte ploidy and pathological mutations in hepatocellular carcinoma: impact on oncogenesis and therapeutics. Glob Health Med 2020;2:273-81. [PMID: 33330821 DOI: 10.35772/ghm.2020.01089] [Reference Citation Analysis]
208 Zeng D, Huang Q, Yu Z, Wu H. Association between aldehyde dehydrogenase 2 gene rs671 G>A polymorphism and alcoholic liver cirrhosis in southern Chinese Hakka population. J Clin Lab Anal 2021;35:e23855. [PMID: 34033144 DOI: 10.1002/jcla.23855] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
209 Gao Z, Chen J, Li X, Shi Y, Tang Z, Liu W, Zhang X, Huang A, Luo X, Gao Q, Shi G, Ke A, Zhou J, Fan J, Fu X, Ding Z. KRAS acting through ERK signaling stabilizes PD-L1 via inhibiting autophagy pathway in intrahepatic cholangiocarcinoma. Cancer Cell Int 2022;22. [DOI: 10.1186/s12935-022-02550-w] [Reference Citation Analysis]
210 Meng P, Zhang YF, Zhang W, Chen X, Xu T, Hu S, Liang X, Feng M, Yang X, Ho M. Identification of the atypical cadherin FAT1 as a novel glypican-3 interacting protein in liver cancer cells. Sci Rep 2021;11:40. [PMID: 33420124 DOI: 10.1038/s41598-020-79524-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
211 Wang L, Wang X, Jia Y, Guo F, Zhengjun S, Shao Z. Intratumoural heterogeneity and clone evolution of oral squamous cell carcinoma. Mol Carcinog 2021;60:758-68. [PMID: 34432915 DOI: 10.1002/mc.23341] [Reference Citation Analysis]
212 Zhang X, Xie K, Zhou H, Wu Y, Li C, Liu Y, Liu Z, Xu Q, Liu S, Xiao D, Tao Y. Role of non-coding RNAs and RNA modifiers in cancer therapy resistance. Mol Cancer 2020;19:47. [PMID: 32122355 DOI: 10.1186/s12943-020-01171-z] [Cited by in Crossref: 29] [Cited by in F6Publishing: 35] [Article Influence: 14.5] [Reference Citation Analysis]
213 Chen S, Wu H, Wang Z, Jia M, Guo J, Jin J, Li X, Meng D, Lin L, He AR, Zhou P, Zhi X. Loss of SPTBN1 Suppresses Autophagy Via SETD7-mediated YAP Methylation in Hepatocellular Carcinoma Initiation and Development. Cell Mol Gastroenterol Hepatol 2021:S2352-345X(21)00234-4. [PMID: 34737104 DOI: 10.1016/j.jcmgh.2021.10.012] [Reference Citation Analysis]
214 Guo J, Hao C, Wang C, Li L. Long noncoding RNA PVT1 modulates hepatocellular carcinoma cell proliferation and apoptosis by recruiting EZH2. Cancer Cell Int 2018;18:98. [PMID: 30008615 DOI: 10.1186/s12935-018-0582-3] [Cited by in Crossref: 32] [Cited by in F6Publishing: 36] [Article Influence: 8.0] [Reference Citation Analysis]
215 Yang F, Ma L, Yang Y, Liu W, Zhao J, Chen X, Wang M, Zhang H, Cheng S, Shen F, Wang H, Zhou W, Cao G. Contribution of Hepatitis B Virus Infection to the Aggressiveness of Primary Liver Cancer: A Clinical Epidemiological Study in Eastern China. Front Oncol 2019;9:370. [PMID: 31179237 DOI: 10.3389/fonc.2019.00370] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
216 Yu Q, Dai J, Shu M. Circular RNA‐0072309 has antitumor influences in Hep3B cell line by targeting microRNA‐665. BioFactors 2020. [DOI: 10.1002/biof.1618] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
217 You Z, Peng D, Cao Y, Zhu Y, Yin J, Zhang G, Peng X. P53 suppresses the progression of hepatocellular carcinoma via miR-15a by decreasing OGT expression and EZH2 stabilization. J Cell Mol Med 2021;25:9168-82. [PMID: 34510715 DOI: 10.1111/jcmm.16792] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
218 Cao X, Zhang G, Li T, Zhou C, Bai L, Zhao J, Tursun T. LINC00657 knockdown suppresses hepatocellular carcinoma progression by sponging miR-424 to regulate PD-L1 expression. Genes Genomics 2020;42:1361-8. [PMID: 32996041 DOI: 10.1007/s13258-020-01001-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
219 Kendall T, Verheij J, Gaudio E, Evert M, Guido M, Goeppert B, Carpino G. Anatomical, histomorphological and molecular classification of cholangiocarcinoma. Liver Int. 2019;39 Suppl 1:7-18. [PMID: 30882996 DOI: 10.1111/liv.14093] [Cited by in Crossref: 67] [Cited by in F6Publishing: 61] [Article Influence: 33.5] [Reference Citation Analysis]
220 Malvi D, de Biase D, Fittipaldi S, Grillini M, Visani M, Pession A, D'Errico A, Vasuri F. Immunomorphology and molecular biology of mixed primary liver cancers: is Nestin a marker of intermediate-cell carcinoma? Histopathology 2020;76:265-74. [PMID: 31374137 DOI: 10.1111/his.13966] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
221 Désert R, Nieto N, Musso O. Dimensions of hepatocellular carcinoma phenotypic diversity. World J Gastroenterol 2018; 24(40): 4536-4547 [PMID: 30386103 DOI: 10.3748/wjg.v24.i40.4536] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
222 Ang CH, Hsu SH, Guo F, Tan CT, Yu VC, Visvader JE, Chow PKH, Fu NY. Lgr5+ pericentral hepatocytes are self-maintained in normal liver regeneration and susceptible to hepatocarcinogenesis. Proc Natl Acad Sci U S A 2019;116:19530-40. [PMID: 31488716 DOI: 10.1073/pnas.1908099116] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 8.7] [Reference Citation Analysis]
223 Wang J, Zhang ZG, Ding ZY, Dong W, Liang HF, Chu L, Zhang BX, Chen XP. IDH1 mutation correlates with a beneficial prognosis and suppresses tumor growth in IHCC. J Surg Res 2018;231:116-25. [PMID: 30278918 DOI: 10.1016/j.jss.2018.04.056] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
224 Zhan K, Bai Y, Liao S, Chen H, Kuang L, Luo Q, Lv L, Qiu L, Mei Z. Identification and validation of EPHX2 as a prognostic biomarker in hepatocellular carcinoma. Mol Med Rep 2021;24:650. [PMID: 34278494 DOI: 10.3892/mmr.2021.12289] [Reference Citation Analysis]
225 Song S, Qiu X. LncRNA miR503HG inhibits epithelial-mesenchymal transition and angiogenesis in hepatocellular carcinoma by enhancing PDCD4 via regulation of miR-15b. Dig Liver Dis 2021;53:107-16. [PMID: 33046427 DOI: 10.1016/j.dld.2020.09.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
226 Zhang D, Guo S, Schrodi SJ. Mechanisms of DNA Methylation in Virus-Host Interaction in Hepatitis B Infection: Pathogenesis and Oncogenetic Properties. Int J Mol Sci 2021;22:9858. [PMID: 34576022 DOI: 10.3390/ijms22189858] [Reference Citation Analysis]
227 He L, Xia Z, Shen J, Zhang X, Peng W, Li C, Wen T. The different effects of adefovir dipivoxil and telbivudine on the prognosis of hepatitis b virus-related hepatocellular carcinoma patients after curative resection. Medicine (Baltimore) 2019;98:e14386. [PMID: 30732177 DOI: 10.1097/MD.0000000000014386] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
228 Tu S, Huang W, Huang C, Luo Z, Yan X. Contextual Regulation of TGF-β Signaling in Liver Cancer. Cells 2019;8:E1235. [PMID: 31614569 DOI: 10.3390/cells8101235] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
229 Bai XS, Zhang C, Peng R, Jiang GQ, Jin SJ, Wang Q, Ke AW, Bai DS. RNF128 Promotes Malignant Behaviors via EGFR/MEK/ERK Pathway in Hepatocellular Carcinoma. Onco Targets Ther 2020;13:10129-41. [PMID: 33116595 DOI: 10.2147/OTT.S269606] [Reference Citation Analysis]
230 Liu J, Dang H, Wang XW. The significance of intertumor and intratumor heterogeneity in liver cancer. Exp Mol Med. 2018;50:e416. [PMID: 29303512 DOI: 10.1038/emm.2017.165] [Cited by in Crossref: 65] [Cited by in F6Publishing: 57] [Article Influence: 16.3] [Reference Citation Analysis]
231 Narsinh KH, Cui J, Papadatos D, Sirlin CB, Santillan CS. Hepatocarcinogenesis and LI-RADS. Abdom Radiol (NY). 2018;43:158-168. [PMID: 29209739 DOI: 10.1007/s00261-017-1409-8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
232 Almutlaq M, Alamro AA, Alamri HS, Alghamdi AA, Barhoumi T. The Effect of Local Renin Angiotensin System in the Common Types of Cancer. Front Endocrinol (Lausanne) 2021;12:736361. [PMID: 34539580 DOI: 10.3389/fendo.2021.736361] [Reference Citation Analysis]
233 Nguyen L, Jager M, Lieshout R, de Ruiter PE, Locati MD, Besselink N, van der Roest B, Janssen R, Boymans S, de Jonge J, IJzermans JNM, Doukas M, Verstegen MMA, van Boxtel R, van der Laan LJW, Cuppen E, Kuijk E. Precancerous liver diseases do not cause increased mutagenesis in liver stem cells. Commun Biol 2021;4:1301. [PMID: 34795391 DOI: 10.1038/s42003-021-02839-y] [Reference Citation Analysis]
234 Cui D, Ni C. LncRNA Lnc712 Promotes Tumorigenesis in Hepatocellular Carcinoma by Targeting miR-142-3p/Bach-1 Axis. Cancer Manag Res 2020;12:11285-94. [PMID: 33177878 DOI: 10.2147/CMAR.S254950] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
235 Li S, Chen Z, Le LQ. New insights into the neurofibroma tumor cells of origin. Neurooncol Adv 2020;2:i13-22. [PMID: 32642729 DOI: 10.1093/noajnl/vdz044] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
236 Dong KS, Chen Y, Yang G, Liao ZB, Zhang HW, Liang HF, Chen XP, Dong HH. TGF-β1 accelerates the hepatitis B virus X-induced malignant transformation of hepatic progenitor cells by upregulating miR-199a-3p. Oncogene 2020;39:1807-20. [PMID: 31740785 DOI: 10.1038/s41388-019-1107-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
237 Sia D, Llovet JM. Liver cancer: Translating '-omics' results into precision medicine for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2017;14:571-2. [PMID: 28765583 DOI: 10.1038/nrgastro.2017.103] [Cited by in F6Publishing: 15] [Reference Citation Analysis]
238 Chang CW, Lo JF, Wang XW. Roles of mitochondria in liver cancer stem cells. Differentiation 2019;107:35-41. [PMID: 31176254 DOI: 10.1016/j.diff.2019.04.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
239 Wang Y, Wu J, Xu J, Lin S. Clinical significance of high expression of stanniocalcin-2 in hepatocellular carcinoma. Biosci Rep 2019;39:BSR20182057. [PMID: 30962272 DOI: 10.1042/BSR20182057] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
240 Lee SE, Alcedo KP, Kim HJ, Snider NT. Alternative Splicing in Hepatocellular Carcinoma. Cell Mol Gastroenterol Hepatol. 2020;10:699-712. [PMID: 32389640 DOI: 10.1016/j.jcmgh.2020.04.018] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
241 Seino S, Tsuchiya A, Watanabe Y, Kawata Y, Kojima Y, Ikarashi S, Yanai H, Nakamura K, Kumaki D, Hirano M, Funakoshi K, Aono T, Sakai T, Sakata J, Takamura M, Kawai H, Yamagiwa S, Wakai T, Terai S. Clinical outcome of hepatocellular carcinoma can be predicted by the expression of hepatic progenitor cell markers and serum tumour markers. Oncotarget 2018;9:21844-60. [PMID: 29774107 DOI: 10.18632/oncotarget.25074] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
242 Lambrecht C, Ferreira GB, Omella JD, Libbrecht L, DE Vos R, Derua R, Mathieu C, Overbergh L, Waelkens E, Janssens V. Differential Proteomic Analysis of Hepatocellular Carcinomas from Ppp2r5d Knockout Mice and Normal (Knockout) Livers. Cancer Genomics Proteomics 2020;17:669-85. [PMID: 33099469 DOI: 10.21873/cgp.20222] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
243 Deng Y, Li P, Liu W, Pu R, Yang F, Song J, Yin J, Han X, Li C, Zhao J, Wang H, Cao G. The genetic polymorphism down-regulating HLA-DRB1 enhancer activity facilitates HBV persistence, evolution and hepatocarcinogenesis in the Chinese Han population. J Viral Hepat 2020;27:1150-61. [PMID: 32568442 DOI: 10.1111/jvh.13353] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
244 Wang S, Zhang C, Li Y, Li P, Zhang D, Li C. Anti-liver cancer effect and the mechanism of arsenic sulfide in vitro and in vivo. Cancer Chemother Pharmacol 2019;83:519-30. [PMID: 30542770 DOI: 10.1007/s00280-018-3755-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
245 Qi X, Chen S, He H, Wen W, Wang H. The role and potential application of extracellular vesicles in liver cancer. Sci China Life Sci 2021;64:1281-94. [PMID: 33847910 DOI: 10.1007/s11427-020-1905-7] [Reference Citation Analysis]
246 Wang J, Huang F, Huang J, Kong J, Liu S, Jin J. Epigenetic analysis of FHL1 tumor suppressor gene in human liver cancer. Oncol Lett 2017;14:6109-16. [PMID: 29113254 DOI: 10.3892/ol.2017.6950] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
247 Zhang Y, Cao N, Gao J, Liang J, Liang Y, Xie Y, Zhou S, Tang X. ASIC1a stimulates the resistance of human hepatocellular carcinoma by promoting EMT via the AKT/GSK3β/Snail pathway driven by TGFβ/Smad signals. J Cellular Molecular Medi. [DOI: 10.1111/jcmm.17288] [Reference Citation Analysis]
248 Wang X, Xu N, Li Q, Chen S, Cheng H, Yang M, Jiang T, Chu J, Ma X, Yin D. Lactonic sophorolipid-induced apoptosis in human HepG2 cells through the Caspase-3 pathway. Appl Microbiol Biotechnol 2021;105:2033-42. [PMID: 33582833 DOI: 10.1007/s00253-020-11045-5] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
249 Wan Z, Wang X. Role of SLC39A6 in the development and progression of liver cancer. Oncol Lett 2022;23:77. [PMID: 35111246 DOI: 10.3892/ol.2022.13197] [Reference Citation Analysis]
250 Peng R, Zhang PF, Yang X, Wei CY, Huang XY, Cai JB, Lu JC, Gao C, Sun HX, Gao Q, Bai DS, Shi GM, Ke AW, Fan J. Overexpression of RNF38 facilitates TGF-β signaling by Ubiquitinating and degrading AHNAK in hepatocellular carcinoma. J Exp Clin Cancer Res 2019;38:113. [PMID: 30836988 DOI: 10.1186/s13046-019-1113-3] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
251 Ding W, Wang H, Zhang Y. Recent insights into the pathogeneses and therapeutic targets of liver diseases: Summary of the 4th Chinese American Liver Society/Society of Chinese Bioscientists in America Hepatology Division Symposium in 2021. Liver Research 2022. [DOI: 10.1016/j.livres.2022.01.002] [Reference Citation Analysis]
252 Gay MD, Safronenka A, Cao H, Liu FH, Malchiodi ZX, Tucker RD, Kroemer A, Shivapurkar N, Smith JP. Targeting the Cholecystokinin Receptor: A Novel Approach for Treatment and Prevention of Hepatocellular Cancer. Cancer Prev Res (Phila) 2021;14:17-30. [PMID: 33115780 DOI: 10.1158/1940-6207.CAPR-20-0220] [Reference Citation Analysis]
253 Chen H, Guan Q, Guo H, Miao L, Zhuo Z. The Genetic Changes of Hepatoblastoma. Front Oncol 2021;11:690641. [PMID: 34367972 DOI: 10.3389/fonc.2021.690641] [Reference Citation Analysis]
254 Ringelhan M, Pfister D, O'Connor T, Pikarsky E, Heikenwalder M. The immunology of hepatocellular carcinoma. Nat Immunol. 2018;19:222-232. [PMID: 29379119 DOI: 10.1038/s41590-018-0044-z] [Cited by in Crossref: 281] [Cited by in F6Publishing: 289] [Article Influence: 70.3] [Reference Citation Analysis]
255 Thilakarathna WPDW, Rupasinghe HPV, Ridgway ND. Mechanisms by Which Probiotic Bacteria Attenuate the Risk of Hepatocellular Carcinoma. Int J Mol Sci 2021;22:2606. [PMID: 33807605 DOI: 10.3390/ijms22052606] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
256 Baldan Ferrari G, Coelho França Quintanilha J, Berlofa Visacri M, Oliveira Vaz C, Cursino MA, Sampaio Amaral L, Brito Bastos, Pereira TT, de Oliveira Guarnieri JP, de Godoy Torso N, Passos Lima CS, Moriel P. Outcomes in hepatocellular carcinoma patients undergoing sorafenib treatment: toxicities, cellular oxidative stress, treatment adherence, and quality of life. Anticancer Drugs 2020;31:523-7. [PMID: 32107349 DOI: 10.1097/CAD.0000000000000902] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
257 Arslan F, Franci G, Maria Nastri B, Pagliano P. Hepatitis B virus-induced hepatocarcinogenesis: A virological and oncological perspective. J Viral Hepat 2021;28:1104-9. [PMID: 34003561 DOI: 10.1111/jvh.13551] [Reference Citation Analysis]
258 Moon H, Park H, Chae MJ, Choi HJ, Kim DY, Ro SW. Activated TAZ induces liver cancer in collaboration with EGFR/HER2 signaling pathways. BMC Cancer 2022;22:423. [PMID: 35439973 DOI: 10.1186/s12885-022-09516-1] [Reference Citation Analysis]
259 Lin CY, Liu YS, Pan KT, Chen CB, Hung CF, Chou CT. The short-term safety and efficacy of TANDEM microspheres of various sizes and doxorubicin loading concentrations for hepatocellular carcinoma treatment. Sci Rep 2021;11:12277. [PMID: 34112836 DOI: 10.1038/s41598-021-91021-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
260 Wang D, Wan B, Zhang X, Sun P, Lu S, Liu C, Zhu L. Nuclear respiratory factor 1 promotes the growth of liver hepatocellular carcinoma cells via E2F1 transcriptional activation. BMC Gastroenterol 2022;22:198. [PMID: 35448958 DOI: 10.1186/s12876-022-02260-7] [Reference Citation Analysis]
261 Benabou E, Salamé Z, Wendum D, Lequoy M, Tahraoui S, Merabtene F, Chrétien Y, Scatton O, Rosmorduc O, Fouassier L, Fartoux L, Praz F, Desbois-Mouthon C. Insulin receptor isoform A favors tumor progression in human hepatocellular carcinoma by increasing stem/progenitor cell features. Cancer Lett 2019;450:155-68. [PMID: 30849481 DOI: 10.1016/j.canlet.2019.02.037] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
262 Zhang Z, Zhang J, Jiang M, Zhao L, Li S, Sun H, Yang F, Liang H. Human Serum Albumin-Based Dual-Agent Delivery Systems for Combination Therapy: Acting against Cancer Cells and Inhibiting Neovascularization in the Tumor Microenvironment. Mol Pharmaceutics 2020;17:1405-14. [DOI: 10.1021/acs.molpharmaceut.0c00133] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
263 Zhang K, Liu H, Yu M, Zhao H, Yang N, Bi X, Sun L, Lin R, Lü G. Upregulated LINC01667 Expression Is Correlated With Poor Prognosis in Hepatocellular Carcinoma. Front Oncol 2021;11:650173. [PMID: 34458133 DOI: 10.3389/fonc.2021.650173] [Reference Citation Analysis]
264 Chiodi I, Mondello C. Life style factors, tumor cell plasticity and cancer stem cells. Mutat Res Rev Mutat Res 2020;784:108308. [PMID: 32430096 DOI: 10.1016/j.mrrev.2020.108308] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
265 Tian G, Sun X, Bai J, Dong J, Zhang B, Gao Z, Wu J. Doxorubicin‑loaded dual‑functional hyaluronic acid nanoparticles: Preparation, characterization and antitumor efficacy in vitro and in vivo. Mol Med Rep 2019;19:133-42. [PMID: 30483793 DOI: 10.3892/mmr.2018.9687] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
266 Nasereldin DS, White LJ, Hodge DO, Roberts LR, Patel T, Antwi SO. Association of metabolic health phenotypes, obesity, and hepatocellular carcinoma risk. Dig Liver Dis 2021:S1590-8658(21)00889-6. [PMID: 34953761 DOI: 10.1016/j.dld.2021.12.002] [Reference Citation Analysis]
267 Dong W, Dai ZH, Liu FC, Guo XG, Ge CM, Ding J, Liu H, Yang F. The RNA-binding protein RBM3 promotes cell proliferation in hepatocellular carcinoma by regulating circular RNA SCD-circRNA 2 production. EBioMedicine 2019;45:155-67. [PMID: 31235426 DOI: 10.1016/j.ebiom.2019.06.030] [Cited by in Crossref: 58] [Cited by in F6Publishing: 62] [Article Influence: 19.3] [Reference Citation Analysis]
268 Huang W, Wu X, Xiang S, Qiao M, Cen X, Pan X, Huang X, Zhao Z. Regulatory mechanism of miR-20a-5p expression in Cancer. Cell Death Discov 2022;8:262. [PMID: 35577802 DOI: 10.1038/s41420-022-01005-5] [Reference Citation Analysis]
269 Zhen SH, Cheng M, Tao YB, Wang YF, Juengpanich S, Jiang ZY, Jiang YK, Yan YY, Lu W, Lue JM, Qian JH, Wu ZY, Sun JH, Lin H, Cai XJ. Deep Learning for Accurate Diagnosis of Liver Tumor Based on Magnetic Resonance Imaging and Clinical Data. Front Oncol. 2020;10:680. [PMID: 32547939 DOI: 10.3389/fonc.2020.00680] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 10.5] [Reference Citation Analysis]
270 Søndergaard JN, Sommerauer C, Atanasoai I, Hinte LC, Geng K, Guiducci G, Bräutigam L, Aouadi M, Stojic L, Barragan I, Kutter C. CCT3-LINC00326 axis regulates hepatocarcinogenic lipid metabolism. Gut 2022:gutjnl-2021-325109. [PMID: 35022268 DOI: 10.1136/gutjnl-2021-325109] [Reference Citation Analysis]
271 Joo I, Lee JM, Yoon JH. Imaging Diagnosis of Intrahepatic and Perihilar Cholangiocarcinoma: Recent Advances and Challenges. Radiology 2018;288:7-13. [DOI: 10.1148/radiol.2018171187] [Cited by in Crossref: 49] [Cited by in F6Publishing: 38] [Article Influence: 12.3] [Reference Citation Analysis]
272 Zhou J, Zhou Q, Shu G, Wang X, Lu Y, Chen H, Hu T, Cai J, Du Y, Yu R. Dual-Effect of Magnetic Resonance Imaging Reporter Gene in Diagnosis and Treatment of Hepatocellular Carcinoma. Int J Nanomedicine 2020;15:7235-49. [PMID: 33061378 DOI: 10.2147/IJN.S257628] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
273 Wang J, Dong M, Xu Z, Song X, Zhang S, Qiao Y, Che L, Gordan J, Hu K, Liu Y, Calvisi DF, Chen X. Notch2 controls hepatocyte-derived cholangiocarcinoma formation in mice. Oncogene. 2018;37:3229-3242. [PMID: 29545603 DOI: 10.1038/s41388-018-0188-1] [Cited by in Crossref: 38] [Cited by in F6Publishing: 33] [Article Influence: 9.5] [Reference Citation Analysis]
274 Huang JY, Li JW, Ling WW, Li T, Luo Y, Liu JB, Lu Q. Can contrast enhanced ultrasound differentiate intrahepatic cholangiocarcinoma from hepatocellular carcinoma? World J Gastroenterol 2020; 26(27): 3938-3951 [PMID: 32774068 DOI: 10.3748/wjg.v26.i27.3938] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
275 Zhang J, Ma X, Fan D. Ginsenoside CK Inhibits Hypoxia-Induced Epithelial-Mesenchymal Transformation through the HIF-1α/NF-κB Feedback Pathway in Hepatocellular Carcinoma. Foods 2021;10:1195. [PMID: 34073155 DOI: 10.3390/foods10061195] [Reference Citation Analysis]
276 Wu X, Ma W, Mei C, Chen X, Yao Y, Liu Y, Qin X, Yuan Y. Description of CRISPR/Cas9 development and its prospect in hepatocellular carcinoma treatment. J Exp Clin Cancer Res. 2020;39:97. [PMID: 32487115 DOI: 10.1186/s13046-020-01603-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
277 Leroy K, Silva Costa CJ, Pieters A, Dos Santos Rodrigues B, Van Campenhout R, Cooreman A, Tabernilla A, Cogliati B, Vinken M. Expression and Functionality of Connexin-Based Channels in Human Liver Cancer Cell Lines. Int J Mol Sci 2021;22:12187. [PMID: 34830068 DOI: 10.3390/ijms222212187] [Reference Citation Analysis]
278 Cho YJ, Lee HH, Kang H, Cho H. The antitumor effect of natural killer cells against hepatocellular carcinoma through CXCL9. Mol Cell Toxicol . [DOI: 10.1007/s13273-021-00215-9] [Reference Citation Analysis]
279 Saffo S, Taddei TH. Systemic Management for Advanced Hepatocellular Carcinoma: A Review of the Molecular Pathways of Carcinogenesis, Current and Emerging Therapies, and Novel Treatment Strategies. Dig Dis Sci. 2019;64:1016-1029. [PMID: 30887150 DOI: 10.1007/s10620-019-05582-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
280 Martín-Sierra C, Colombo S, Martins R, Laranjeira P, Melo T, Abrantes AM, Oliveira RC, Tralhão JG, Botelho MF, Furtado E, Domingues P, Domingues MR, Paiva A. Tumor Resection Induces Alterations on Serum Phospholipidome of Liver Cancer Patients. Lipids 2020;55:185-91. [PMID: 32045496 DOI: 10.1002/lipd.12221] [Reference Citation Analysis]
281 Rivas M, Johnston ME 2nd, Gulati R, Kumbaji M, Margues Aguiar TF, Timchenko L, Krepischi A, Shin S, Bondoc A, Tiao G, Geller J, Timchenko N. HDAC1-Dependent Repression of Markers of Hepatocytes and P21 Is Involved in Development of Pediatric Liver Cancer. Cell Mol Gastroenterol Hepatol 2021:S2352-345X(21)00141-7. [PMID: 34245919 DOI: 10.1016/j.jcmgh.2021.06.026] [Reference Citation Analysis]
282 Li L, Li X, Zhang Q, Ye T, Zou S, Yan J. EIF5A expression and its role as a potential diagnostic biomarker in hepatocellular carcinoma. J Cancer 2021;12:4774-9. [PMID: 34234848 DOI: 10.7150/jca.58168] [Reference Citation Analysis]
283 Unfried JP, Sangro P, Prats-Mari L, Sangro B, Fortes P. The Landscape of lncRNAs in Hepatocellular Carcinoma: A Translational Perspective. Cancers (Basel) 2021;13:2651. [PMID: 34071216 DOI: 10.3390/cancers13112651] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
284 Wu C, Tang G, Wang X, Zhang J, Chen S, Lu C, Zhang D, Li Y. Micro-RNA-21 rs1292037 A>G polymorphism can predict hepatocellular carcinoma prognosis (HCC), and plays a key role in cell proliferation and ischemia-reperfusion injury (IRI) in HCC cell model of IRI. Saudi Med J 2020;41:383-92. [PMID: 32291425 DOI: 10.15537/smj.2020.4.24994] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
285 Chen J, Yang J, Xu Q, Wang Z, Wu J, Pan L, Huang K, Wang C. Integrated bioinformatics analysis identified MTHFD1L as a potential biomarker and correlated with immune infiltrates in hepatocellular carcinoma. Biosci Rep 2021;41:BSR20202063. [PMID: 33605411 DOI: 10.1042/BSR20202063] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
286 Malenica I, Donadon M, Lleo A. Molecular and Immunological Characterization of Biliary Tract Cancers: A Paradigm Shift Towards a Personalized Medicine. Cancers (Basel) 2020;12:E2190. [PMID: 32781527 DOI: 10.3390/cancers12082190] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 8.5] [Reference Citation Analysis]
287 Liu X, Ren H, Guo H, Wang W, Zhao N. Interleukin-35 has a tumor-promoting role in hepatocellular carcinoma. Clin Exp Immunol 2021;203:219-29. [PMID: 33030251 DOI: 10.1111/cei.13535] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
288 Goldaracena N, Gorgen A, Sapisochin G. Current status of liver transplantation for cholangiocarcinoma. Liver Transpl. 2018;24:294-303. [PMID: 29024405 DOI: 10.1002/lt.24955] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 9.5] [Reference Citation Analysis]
289 Xu R, Ding Z, Zhao Q, Ke T, Chen S, Wang X, Wang Y, Sheng M, Wang W, Long N, Shen Y, Xu Y, Shao W. An Alternatively Spliced Variant of METTL3 Mediates Tumor Suppression in Hepatocellular Carcinoma. Genes 2022;13:669. [DOI: 10.3390/genes13040669] [Reference Citation Analysis]
290 Tian G, Pan R, Zhang B, Qu M, Lian B, Jiang H, Gao Z, Wu J. Liver-Targeted Combination Therapy Basing on Glycyrrhizic Acid-Modified DSPE-PEG-PEI Nanoparticles for Co-delivery of Doxorubicin and Bcl-2 siRNA. Front Pharmacol 2019;10:4. [PMID: 30723405 DOI: 10.3389/fphar.2019.00004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
291 Xie L, Li M, Liu D, Wang X, Wang P, Dai H, Yang W, Liu W, Hu X, Zhao M. Secalonic Acid-F, a Novel Mycotoxin, Represses the Progression of Hepatocellular Carcinoma via MARCH1 Regulation of the PI3K/AKT/β-catenin Signaling Pathway. Molecules 2019;24:E393. [PMID: 30678274 DOI: 10.3390/molecules24030393] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
292 Wang W, Zhang M, Peng Y, He J. Ubiquitin Associated Protein 2-Like (UBAP2L) Overexpression in Patients with Hepatocellular Carcinoma and its Clinical Significance. Med Sci Monit 2017;23:4779-88. [PMID: 28981479 DOI: 10.12659/msm.907071] [Cited by in Crossref: 4] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
293 Tseng HC, Xiong W, Badeti S, Yang Y, Ma M, Liu T, Ramos CA, Dotti G, Fritzky L, Jiang JG, Yi Q, Guarrera J, Zong WX, Liu C, Liu D. Efficacy of anti-CD147 chimeric antigen receptors targeting hepatocellular carcinoma. Nat Commun 2020;11:4810. [PMID: 32968061 DOI: 10.1038/s41467-020-18444-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
294 Cheng Z, He Z, Cai Y, Zhang C, Fu G, Li H, Sun W, Liu C, Cui X, Ning B, Xiang D, Zhou T, Li X, Xie W, Wang H, Ding J. Conversion of hepatoma cells to hepatocyte-like cells by defined hepatocyte nuclear factors. Cell Res 2019;29:124-35. [PMID: 30560924 DOI: 10.1038/s41422-018-0111-x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 6.5] [Reference Citation Analysis]
295 Qi T, Dong Y, Gao Z, Xu J. Research Progress on the Anti-Cancer Molecular Mechanisms of Huaier. Onco Targets Ther 2020;13:12587-99. [PMID: 33335400 DOI: 10.2147/OTT.S281328] [Reference Citation Analysis]
296 Sha M, Jeong S, Qiu BJ, Tong Y, Xia L, Xu N, Zhang JJ, Xia Q. Isolation of cancer-associated fibroblasts and its promotion to the progression of intrahepatic cholangiocarcinoma. Cancer Med. 2018;7:4665-4677. [PMID: 30062820 DOI: 10.1002/cam4.1704] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
297 Zhang Z, Yang G, Fan F, Zhong C, Yuan Y, Zhang X, Chang S. Terahertz circular dichroism sensing of living cancer cells based on microstructure sensor. Anal Chim Acta 2021;1180:338871. [PMID: 34538326 DOI: 10.1016/j.aca.2021.338871] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
298 Chen J, Debebe A, Zeng N, Kopp J, He L, Sander M, Stiles BL. Transformation of SOX9+ cells by Pten deletion synergizes with steatotic liver injury to drive development of hepatocellular and cholangiocarcinoma. Sci Rep 2021;11:11823. [PMID: 34083580 DOI: 10.1038/s41598-021-90958-1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
299 Wu Y, Wang PS, Wang BG, Xu L, Fang WX, Che XF, Qu XJ, Liu YP, Li Z. Genomewide identification of a novel six-LncRNA signature to improve prognosis prediction in resectable hepatocellular carcinoma. Cancer Med. 2018;7:6219-6233. [PMID: 30378276 DOI: 10.1002/cam4.1854] [Cited by in Crossref: 19] [Cited by in F6Publishing: 23] [Article Influence: 4.8] [Reference Citation Analysis]
300 Lv X, Yu H, Zhang Q, Huang Q, Hong X, Yu T, Lan H, Mei C, Zhang W, Luo H, Pang P, Shan H. SRXN1 stimulates hepatocellular carcinoma tumorigenesis and metastasis through modulating ROS/p65/BTG2 signalling. J Cell Mol Med 2020;24:10714-29. [PMID: 32746503 DOI: 10.1111/jcmm.15693] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
301 Zheng Y, Li Y, Feng J, Li J, Ji J, Wu L, Yu Q, Dai W, Wu J, Zhou Y, Guo C. Cellular based immunotherapy for primary liver cancer. J Exp Clin Cancer Res 2021;40:250. [PMID: 34372912 DOI: 10.1186/s13046-021-02030-5] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
302 Ruman U, Buskaran K, Pastorin G, Masarudin MJ, Fakurazi S, Hussein MZ. Synthesis and Characterization of Chitosan-Based Nanodelivery Systems to Enhance the Anticancer Effect of Sorafenib Drug in Hepatocellular Carcinoma and Colorectal Adenocarcinoma Cells. Nanomaterials (Basel) 2021;11:497. [PMID: 33669332 DOI: 10.3390/nano11020497] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
303 Li C, Salmen SH, Awad Alahmadi T, Priya Veeraraghavan V, Krishna Mohan S, Natarajan N, Subramanian S. Anticancer effect of Selenium/Chitosan/Polyethylene glycol/Allyl isothiocyanate nanocomposites against diethylnitrosamine-induced liver cancer in rats. Saudi Journal of Biological Sciences 2022. [DOI: 10.1016/j.sjbs.2022.02.012] [Reference Citation Analysis]
304 Liu M, Yan Q, Sun Y, Nam Y, Hu L, Loong JH, Ouyang Q, Zhang Y, Li HL, Kong FE, Li L, Li Y, Li MM, Cheng W, Jiang LX, Fang S, Yang XD, Mo JQ, Gong YF, Tang YQ, Li Y, Yuan YF, Ma NF, Lin G, Ma S, Wang JG, Guan XY. A hepatocyte differentiation model reveals two subtypes of liver cancer with different oncofetal properties and therapeutic targets. Proc Natl Acad Sci U S A 2020;117:6103-13. [PMID: 32123069 DOI: 10.1073/pnas.1912146117] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
305 Peng Z, Cao G, Hou Q, Li L, Ying S, Sun J, Zhou G, Zhou J, Zhang X, Ji W, Yu Z, Li T, Zhu D, Hu W, Ji J, Du H, Shi C, Guo X, Fang J, Han J, Gu W, Xie X, Sun Z, Xu H, Wu X, Hu T, Huang J, Hu H, Zheng J, Luo J, Chen Y, Yu W, Shao G. The Comprehensive Analysis of Efficacy and Safety of CalliSpheres® Drug-Eluting Beads Transarterial Chemoembolization in 367 Liver Cancer Patients: A Multiple-Center, Cohort Study. Oncol Res 2020;28:249-71. [PMID: 31856933 DOI: 10.3727/096504019X15766663541105] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
306 Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, Lencioni R, Koike K, Zucman-Rossi J, Finn RS. Hepatocellular carcinoma. Nat Rev Dis Primers 2021;7:6. [PMID: 33479224 DOI: 10.1038/s41572-020-00240-3] [Cited by in Crossref: 96] [Cited by in F6Publishing: 108] [Article Influence: 96.0] [Reference Citation Analysis]
307 Ren S, Li Q, Liu S, Qi Q, Duan S, Mao B, Li X, Wu Y, Zhang L. Clinical Value of Machine Learning-Based Ultrasomics in Preoperative Differentiation Between Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma: A Multicenter Study. Front Oncol 2021;11:749137. [PMID: 34804935 DOI: 10.3389/fonc.2021.749137] [Reference Citation Analysis]
308 Du L, Wang L, Yang H, Duan J, Lai J, Wu W, Fan S, Zhi X. Sex Comb on Midleg Like-2 Accelerates Hepatocellular Carcinoma Cell Proliferation and Metastasis by Activating Wnt/β-Catenin/EMT Signaling. Yonsei Med J 2021;62:1073-82. [PMID: 34816637 DOI: 10.3349/ymj.2021.62.12.1073] [Reference Citation Analysis]
309 Goya T, Horisawa K, Udono M, Ohkawa Y, Ogawa Y, Sekiya S, Suzuki A. Direct Conversion of Human Endothelial Cells Into Liver Cancer‐Forming Cells Using Nonintegrative Episomal Vectors. Hepatology Communications. [DOI: 10.1002/hep4.1911] [Reference Citation Analysis]
310 Chen L, Yi X, Guo P, Guo H, Chen Z, Hou C, Qi L, Wang Y, Li C, Liu P, Liu Y, Xu Y, Zhang N. The role of bone marrow-derived cells in the origin of liver cancer revealed by single-cell sequencing. Cancer Biol Med 2020;17:142-53. [PMID: 32296582 DOI: 10.20892/j.issn.2095-3941.2019.0369] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
311 Yang H, Deng Q, Ni T, Liu Y, Lu L, Dai H, Wang H, Yang W. Targeted Inhibition of LPL/FABP4/CPT1 fatty acid metabolic axis can effectively prevent the progression of nonalcoholic steatohepatitis to liver cancer. Int J Biol Sci 2021;17:4207-22. [PMID: 34803493 DOI: 10.7150/ijbs.64714] [Reference Citation Analysis]
312 Oriakhi M, Andrabi SA, Olutoyin A, Ahluwalia M. A Rare Presentation of Hepatocellular Carcinoma Infiltrating the Gallbladder. Cureus 2019;11:e5140. [PMID: 31523569 DOI: 10.7759/cureus.5140] [Reference Citation Analysis]
313 Lalazar G, Simon SM. Fibrolamellar Carcinoma: Recent Advances and Unresolved Questions on the Molecular Mechanisms. Semin Liver Dis 2018;38:51-9. [PMID: 29471565 DOI: 10.1055/s-0037-1621710] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
314 Ma L, Wang XW. Dissecting liver tumor heterogeneity to improve health equity. Trends Cancer 2022:S2405-8033(21)00249-1. [PMID: 35012904 DOI: 10.1016/j.trecan.2021.12.001] [Reference Citation Analysis]
315 Singh D, Singh M. Hepatocellular-Targeted mRNA Delivery Using Functionalized Selenium Nanoparticles In Vitro. Pharmaceutics 2021;13:298. [PMID: 33668320 DOI: 10.3390/pharmaceutics13030298] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
316 Kang Y, Cai Y, Yang Y. The gut microbiome and hepatocellular carcinoma: Implications for early diagnostic biomarkers and novel therapies. Liver Cancer. [DOI: 10.1159/000521358] [Reference Citation Analysis]
317 Zhang X, Jiang D, Yang S, Sun Y, Liu Y, Shi J, Hu C, Pan J, Liu T, Jin B, Yang K. BAP31 Promotes Tumor Cell Proliferation by Stabilizing SERPINE2 in Hepatocellular Carcinoma. Front Cell Dev Biol 2020;8:607906. [PMID: 33363167 DOI: 10.3389/fcell.2020.607906] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
318 Yuen VW, Wong CC. Hypoxia-inducible factors and innate immunity in liver cancer. J Clin Invest 2020;130:5052-62. [PMID: 32750043 DOI: 10.1172/JCI137553] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
319 Wu R, Guo W, Qiu X, Wang S, Sui C, Lian Q, Wu J, Shan Y, Yang Z, Yang S, Wu T, Wang K, Zhu Y, Wang S, Liu C, Zhang Y, Zheng B, Li Z, Zhang Y, Shen S, Zhao Y, Wang W, Bao J, Hu J, Wu X, Jiang X, Wang H, Gu J, Chen L. Comprehensive analysis of spatial architecture in primary liver cancer. Sci Adv 2021;7:eabg3750. [PMID: 34919432 DOI: 10.1126/sciadv.abg3750] [Reference Citation Analysis]
320 Wang J, Huang J, Ma Q, Liu G. Association between quantitative parameters of CEUS and Sall4/Wnt/β-catenin signaling in patients with hepatocellular carcinoma. Cancer Manag Res 2019;11:3339-47. [PMID: 31114369 DOI: 10.2147/CMAR.S199968] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
321 Guo Y, Zhao YR, Liu H, Xin Y, Yu JZ, Zang YJ, Xu QG. EHMT2 promotes the pathogenesis of hepatocellular carcinoma by epigenetically silencing APC expression. Cell Biosci 2021;11:152. [PMID: 34344448 DOI: 10.1186/s13578-021-00663-9] [Reference Citation Analysis]
322 Lee K, Song YS, Shin Y, Wen X, Kim Y, Cho NY, Bae JM, Kang GH. Intrahepatic cholangiocarcinomas with IDH1/2 mutation-associated hypermethylation at selective genes and their clinicopathological features. Sci Rep 2020;10:15820. [PMID: 32978444 DOI: 10.1038/s41598-020-72810-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
323 Zhou Y, Huan L, Wu Y, Bao C, Chen B, Wang L, Huang S, Liang L, He X. LncRNA ID2-AS1 suppresses tumor metastasis by activating the HDAC8/ID2 pathway in hepatocellular carcinoma. Cancer Letters 2020;469:399-409. [DOI: 10.1016/j.canlet.2019.11.007] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 8.5] [Reference Citation Analysis]
324 Wang PC, Hu ZQ, Zhou SL, Zhan H, Zhou ZJ, Luo CB, Huang XW. Downregulation of MAGE family member H1 enhances hepatocellular carcinoma progression and serves as a biomarker for patient prognosis. Future Oncol 2018;14:1177-86. [PMID: 29316827 DOI: 10.2217/fon-2017-0672] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
325 Chen S. LINC00852 Regulates Cell Proliferation, Invasion, Migration and Apoptosis in Hepatocellular Carcinoma Via the miR-625/E2F1 Axis. Cel Mol Bioeng . [DOI: 10.1007/s12195-021-00714-8] [Reference Citation Analysis]
326 Nair B, Nath LR. Inevitable role of TGF-β1 in progression of nonalcoholic fatty liver disease. Journal of Receptors and Signal Transduction 2020;40:195-200. [DOI: 10.1080/10799893.2020.1726952] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
327 Hu M, Li M, Huang H, Lu C. Isolated cancer stem cells from human liver cancer: morphological and functional characteristics in primary culture. Clin Transl Oncol 2021. [PMID: 34169442 DOI: 10.1007/s12094-021-02667-w] [Reference Citation Analysis]
328 Tuo H, Wang Y, Wang L, Yao B, Li Q, Wang C, Liu Z, Han S, Yin G, Tu K, Liu Q. MiR-324-3p promotes tumor growth through targeting DACT1 and activation of Wnt/β-catenin pathway in hepatocellular carcinoma. Oncotarget 2017;8:65687-98. [PMID: 29029464 DOI: 10.18632/oncotarget.20058] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 4.8] [Reference Citation Analysis]
329 Wang J, Wang H, Peters M, Ding N, Ribback S, Utpatel K, Cigliano A, Dombrowski F, Xu M, Chen X, Song X, Che L, Evert M, Cossu A, Gordan J, Zeng Y, Chen X, Calvisi DF. Loss of Fbxw7 synergizes with activated Akt signaling to promote c-Myc dependent cholangiocarcinogenesis. J Hepatol 2019;71:742-52. [PMID: 31195063 DOI: 10.1016/j.jhep.2019.05.027] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
330 Ohni S, Yamaguchi H, Hirotani Y, Nakanishi Y, Midorikawa Y, Sugitani M, Naruse H, Nakayama T, Makishima M, Esumi M. Direct molecular evidence for both multicentric and monoclonal carcinogenesis followed by transdifferentiation from hepatocellular carcinoma to cholangiocarcinoma in a case of metachronous liver cancer. Oncol Lett 2022;23:22. [PMID: 34868359 DOI: 10.3892/ol.2021.13140] [Reference Citation Analysis]
331 Jayant K, Habib N, Huang KW, Warwick J, Arasaradnam R. Recent Advances: The Imbalance of Immune Cells and Cytokines in the Pathogenesis of Hepatocellular Carcinoma. Diagnostics (Basel). 2020;10. [PMID: 32466214 DOI: 10.3390/diagnostics10050338] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
332 Beaufrère A, Calderaro J, Paradis V. Combined hepatocellular-cholangiocarcinoma: An update. J Hepatol 2021;74:1212-24. [PMID: 33545267 DOI: 10.1016/j.jhep.2021.01.035] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
333 Sun D, Liu Y, Wang H, Deng F, Zhang Y, Zhao S, Ma X, Wu H, Sun G. Novel decellularized liver matrix-alginate hybrid gel beads for the 3D culture of hepatocellular carcinoma cells. International Journal of Biological Macromolecules 2018;109:1154-63. [DOI: 10.1016/j.ijbiomac.2017.11.103] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
334 Shiao MS, Chiablaem K, Charoensawan V, Ngamphaiboon N, Jinawath N. Emergence of Intrahepatic Cholangiocarcinoma: How High-Throughput Technologies Expedite the Solutions for a Rare Cancer Type. Front Genet 2018;9:309. [PMID: 30158952 DOI: 10.3389/fgene.2018.00309] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
335 Nie H, Wang Y, Liao Z, Zhou J, Ou C. The function and mechanism of circular RNAs in gastrointestinal tumours. Cell Prolif 2020;53:e12815. [PMID: 32515024 DOI: 10.1111/cpr.12815] [Cited by in Crossref: 8] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
336 Aissa AF, Tryndyak VP, de Conti A, Rita Thomazela Machado A, Tuttis K, da Silva Machado C, Hernandes LC, Wellington da Silva Santos P, Mara Serpeloni J, P Pogribny I, Maria Greggi Antunes L. Epigenetic changes induced in mice liver by methionine-supplemented and methionine-deficient diets. Food Chem Toxicol 2022;163:112938. [PMID: 35314295 DOI: 10.1016/j.fct.2022.112938] [Reference Citation Analysis]
337 Zhang S, Chen ZW, Meng SM, Ding QL, Zhong ZB, Wei YH, Ye QF, Hu KH. Eukaryotic initiation factor 3e subunit is positively associated with tumorigenesis and development of hepatocellular carcinoma. Shijie Huaren Xiaohua Zazhi 2020; 28(12): 475-485 [DOI: 10.11569/wcjd.v28.i12.475] [Reference Citation Analysis]
338 Yang F, Deng K, Zheng H, Liu Z, Zheng Y. Progress of targeted and immunotherapy for hepatocellular carcinoma and the application of next-generation sequencing. Annals of Hepatology 2022. [DOI: 10.1016/j.aohep.2022.100677] [Reference Citation Analysis]
339 Chen YH, Wu WK, Wu MS. Microbiota-Associated Therapy for Non-Alcoholic Steatohepatitis-Induced Liver Cancer: A Review. Int J Mol Sci 2020;21:E5999. [PMID: 32825440 DOI: 10.3390/ijms21175999] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
340 Wu X, Chen R, Zheng W, Hu H. Comprehensive Analysis of Factors Affecting Clinical Response and Short-Term Survival to Drug-Eluting Bead Transarterial Chemoembolization for Treatment in Patients With Liver Cancer. Technol Cancer Res Treat 2018;17:1533033818759878. [PMID: 29739274 DOI: 10.1177/1533033818759878] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
341 Gunasekhar P, Vijayalakshmi S. Optimal biomarker selection using adaptive Social Ski-Driver optimization for liver cancer detection. Biocybernetics and Biomedical Engineering 2020;40:1611-25. [DOI: 10.1016/j.bbe.2020.10.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
342 Sunami Y. NASH, Fibrosis and Hepatocellular Carcinoma: Lipid Synthesis and Glutamine/Acetate Signaling. Int J Mol Sci 2020;21:E6799. [PMID: 32947972 DOI: 10.3390/ijms21186799] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
343 Jin J, Xu H, Li W, Xu X, Liu H, Wei F. LINC00346 Acts as a Competing Endogenous RNA Regulating Development of Hepatocellular Carcinoma via Modulating CDK1/CCNB1 Axis. Front Bioeng Biotechnol. 2020;8:54. [PMID: 32133348 DOI: 10.3389/fbioe.2020.00054] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 7.5] [Reference Citation Analysis]
344 Ran Z, Wu S, Ma Z, Chen X, Liu J, Yang J. Advances in exosome biomarkers for cervical cancer. Cancer Med 2022. [PMID: 35578572 DOI: 10.1002/cam4.4828] [Reference Citation Analysis]
345 Wang J, Xia C, Pu M, Dai B, Yang X, Shang R, Yang Z, Zhang R, Tao K, Dou K. Silencing of CDCA5 inhibits cancer progression and serves as a prognostic biomarker for hepatocellular carcinoma. Oncol Rep 2018;40:1875-84. [PMID: 30015982 DOI: 10.3892/or.2018.6579] [Cited by in Crossref: 6] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
346 Wang L, Pan X, Qin J. Value of ultrasonography in the diagnosis of primary hepatic carcinoma and thyroid carcinoma. Oncol Lett 2018;16:5223-9. [PMID: 30250591 DOI: 10.3892/ol.2018.9272] [Reference Citation Analysis]
347 An C, Kim MJ. Imaging features related with prognosis of hepatocellular carcinoma. Abdom Radiol (NY) 2019;44:509-16. [PMID: 30171295 DOI: 10.1007/s00261-018-1758-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
348 Muenzner JK, Kunze P, Lindner P, Polaschek S, Menke K, Eckstein M, Geppert CI, Chanvorachote P, Baeuerle T, Hartmann A, Schneider-Stock R. Generation and characterization of hepatocellular carcinoma cell lines with enhanced cancer stem cell potential. J Cell Mol Med 2018;22:6238-48. [PMID: 30280520 DOI: 10.1111/jcmm.13911] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
349 Rani B, Malfettone A, Dituri F, Soukupova J, Lupo L, Mancarella S, Fabregat I, Giannelli G. Galunisertib suppresses the staminal phenotype in hepatocellular carcinoma by modulating CD44 expression. Cell Death Dis 2018;9:373. [PMID: 29515105 DOI: 10.1038/s41419-018-0384-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
350 Kyrochristos ID, Ziogas DE, Roukos DH. Regorafenib: a newly approved drug for advanced hepatocellular carcinoma. Future Oncol 2017;13:1665-8. [PMID: 28613123 DOI: 10.2217/fon-2017-0237] [Reference Citation Analysis]
351 Lin X, Li AM, Li YH, Luo RC, Zou YJ, Liu YY, Liu C, Xie YY, Zuo S, Liu Z, Liu Z, Fang WY. Silencing MYH9 blocks HBx-induced GSK3β ubiquitination and degradation to inhibit tumor stemness in hepatocellular carcinoma. Signal Transduct Target Ther 2020;5:13. [PMID: 32296025 DOI: 10.1038/s41392-020-0111-4] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 10.5] [Reference Citation Analysis]
352 Tietze L, Kessler SM. The Good, the Bad, the Question-H19 in Hepatocellular Carcinoma. Cancers (Basel) 2020;12:E1261. [PMID: 32429417 DOI: 10.3390/cancers12051261] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
353 Wu S, Liu S, Li Y, Liu C, Pan H. Lestaurtinib Has the Potential to Inhibit the Proliferation of Hepatocellular Carcinoma Uncovered by Bioinformatics Analysis and Pharmacological Experiments. Front Cell Dev Biol 2022;10:837428. [DOI: 10.3389/fcell.2022.837428] [Reference Citation Analysis]
354 Wang J, Zhang N, Han Q, Lu W, Wang L, Yang D, Zheng M, Zhang Z, Liu H, Lee TH, Zhou XZ, Lu KP. Pin1 inhibition reverses the acquired resistance of human hepatocellular carcinoma cells to Regorafenib via the Gli1/Snail/E-cadherin pathway. Cancer Lett 2019;444:82-93. [PMID: 30583078 DOI: 10.1016/j.canlet.2018.12.010] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 4.5] [Reference Citation Analysis]
355 Liu Y, Zhuo S, Zhou Y, Ma L, Sun Z, Wu X, Wang XW, Gao B, Yang Y. Yap-Sox9 signaling determines hepatocyte plasticity and lineage-specific hepatocarcinogenesis. J Hepatol 2021:S0168-8278(21)02182-6. [PMID: 34793870 DOI: 10.1016/j.jhep.2021.11.010] [Reference Citation Analysis]
356 Yu J, Yuan X, Sjöholm L, Liu T, Kong F, Ekström TJ, Björkholm M, Xu D. Telomerase reverse transcriptase regulates DNMT3B expression/aberrant DNA methylation phenotype and AKT activation in hepatocellular carcinoma. Cancer Lett 2018;434:33-41. [PMID: 30017965 DOI: 10.1016/j.canlet.2018.07.013] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 5.5] [Reference Citation Analysis]
357 Hong Z, Lu Y, Ran C, Tang P, Huang J, Yang Y, Duan X, Wu H. The bioactive ingredients in Actinidia chinensis Planch. Inhibit liver cancer by inducing apoptosis. J Ethnopharmacol 2021;281:114553. [PMID: 34428524 DOI: 10.1016/j.jep.2021.114553] [Reference Citation Analysis]
358 Dai Q, Zhang C, Yuan Z, Sun Q, Jiang Y. Current discovery strategies for hepatocellular carcinoma therapeutics. Expert Opinion on Drug Discovery 2020;15:243-58. [DOI: 10.1080/17460441.2020.1696769] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
359 Guo Z, Zhou Y, Yang J, Shao X. Dendrobium candidum extract inhibits proliferation and induces apoptosis of liver cancer cells by inactivating Wnt/β-catenin signaling pathway. Biomed Pharmacother 2019;110:371-9. [PMID: 30529770 DOI: 10.1016/j.biopha.2018.11.149] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
360 Lim LJ, Ling LH, Neo YP, Chung AYF, Goh BKP, Chow PKH, Chan CY, Cheow PC, Lee SY, Lim TKH, Chong SS, Ooi LLPJ, Lee CG. Highly deregulated lncRNA LOC is associated with overall worse prognosis in Hepatocellular Carcinoma patients. J Cancer 2021;12:3098-113. [PMID: 33976720 DOI: 10.7150/jca.56340] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
361 Kim MK, Shin SJ, Lee HM, Choi HS, Jeong J, Kim H, Paik SS, Kim M, Choi D, Ryu CJ. Mycoplasma infection promotes tumor progression via interaction of the mycoplasmal protein p37 and epithelial cell adhesion molecule in hepatocellular carcinoma. Cancer Lett 2019;454:44-52. [PMID: 30980864 DOI: 10.1016/j.canlet.2019.04.007] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
362 Xu X, Mao Y, Tang Y, Liu Y, Xue C, Yue Q, Liu Q, Wang J, Yin Y, Yang J. Classification of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma Based on Radiomic Analysis. Computational and Mathematical Methods in Medicine 2022;2022:1-9. [DOI: 10.1155/2022/5334095] [Reference Citation Analysis]
363 Cadoux M, Caruso S, Pham S, Gougelet A, Pophillat C, Riou R, Loesch R, Colnot S, Nguyen CT, Calderaro J, Celton-morizur S, Guerra N, Zucman-rossi J, Desdouets C, Couty J. Expression of NKG2D ligands is downregulated by β-catenin signalling and associates with HCC aggressiveness. Journal of Hepatology 2021;74:1386-97. [DOI: 10.1016/j.jhep.2021.01.017] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
364 Xiao F, Li H, Feng Z, Huang L, Kong L, Li M, Wang D, Liu F, Zhu Z, Wei Y, Zhang W. Intermedin facilitates hepatocellular carcinoma cell survival and invasion via ERK1/2-EGR1/DDIT3 signaling cascade. Sci Rep 2021;11:488. [PMID: 33436794 DOI: 10.1038/s41598-020-80066-x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
365 He S, Zhang J, Zhang W, Chen F, Luo R. FOXA1 inhibits hepatocellular carcinoma progression by suppressing PIK3R1 expression in male patients. J Exp Clin Cancer Res 2017;36:175. [PMID: 29208003 DOI: 10.1186/s13046-017-0646-6] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 4.4] [Reference Citation Analysis]
366 Pollicino T, Musolino C, Saitta C, Tripodi G, Lanza M, Raffa G, Tocco FCD, Raggi C, Bragazzi MC, Barbera A, Navarra G, Invernizzi P, Alvaro D, Raimondo G. Free episomal and integrated HBV DNA in HBsAg-negative patients with intrahepatic cholangiocarcinoma. Oncotarget. 2019;10:3931-3938. [PMID: 31231470 DOI: 10.18632/oncotarget.27002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
367 Xu G, Ye J, Liu X, Zhang N, Zhao Y, Fan J, Liu X, Wu J. Activation of pluripotent genes in hepatic progenitor cells in the transition of nonalcoholic steatohepatitis to pre-malignant lesions. Lab Invest 2017;97:1201-17. [DOI: 10.1038/labinvest.2017.84] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
368 Bartolini I, Risaliti M, Tucci R, Muiesan P, Ringressi MN, Taddei A, Amedei A. Gut microbiota and immune system in liver cancer: Promising therapeutic implication from development to treatment. World J Gastrointest Oncol 2021; 13(11): 1616-1631 [PMID: 34853639 DOI: 10.4251/wjgo.v13.i11.1616] [Reference Citation Analysis]
369 Vicent S, Lieshout R, Saborowski A, Verstegen MMA, Raggi C, Recalcati S, Invernizzi P, van der Laan LJW, Alvaro D, Calvisi DF, Cardinale V. Experimental models to unravel the molecular pathogenesis, cell of origin and stem cell properties of cholangiocarcinoma. Liver Int 2019;39 Suppl 1:79-97. [PMID: 30851232 DOI: 10.1111/liv.14094] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
370 Yang F, Wan Y, Xu L, Wu Y, Shen X, Wang J, Lu D, Shao C, Zheng S, Niu T, Xu X. MRI-Radiomics Prediction for Cytokeratin 19-Positive Hepatocellular Carcinoma: A Multicenter Study. Front Oncol 2021;11:672126. [PMID: 34476208 DOI: 10.3389/fonc.2021.672126] [Reference Citation Analysis]
371 Li D, Hu M, Liu Y, Ye P, Du P, Li CS, Cheng L, Liu P, Jiang J, Su L, Wang S, Zheng P, Liu Y. CD24-p53 axis suppresses diethylnitrosamine-induced hepatocellular carcinogenesis by sustaining intrahepatic macrophages. Cell Discov 2018;4:6. [PMID: 29423273 DOI: 10.1038/s41421-017-0007-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
372 Hu J, Wang YN, Song DJ, Tan JP, Cao Y, Fan J, Wang Z, Zhou J. A High-Accuracy Model Based on Plasma miRNAs Diagnoses Intrahepatic Cholangiocarcinoma: A Single Center with 1001 Samples. Diagnostics (Basel) 2021;11:610. [PMID: 33805513 DOI: 10.3390/diagnostics11040610] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
373 Zhang C, Yang M, Ericsson AC. The Potential Gut Microbiota-Mediated Treatment Options for Liver Cancer. Front Oncol 2020;10:524205. [PMID: 33163393 DOI: 10.3389/fonc.2020.524205] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
374 Li MM, Tang YQ, Gong YF, Cheng W, Li HL, Kong FE, Zhu WJ, Liu SS, Huang L, Guan XY, Ma NF, Liu M. Development of an oncogenic dedifferentiation SOX signature with prognostic significance in hepatocellular carcinoma. BMC Cancer 2019;19:851. [PMID: 31462277 DOI: 10.1186/s12885-019-6041-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
375 Jayant K, Habib N, Huang KW, Podda M, Warwick J, Arasaradnam R. Immunological Basis of Genesis of Hepatocellular Carcinoma: Unique Challenges and Potential Opportunities through Immunomodulation. Vaccines (Basel) 2020;8:E247. [PMID: 32456200 DOI: 10.3390/vaccines8020247] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
376 Piorońska W, Nwosu ZC, Han M, Büttner M, Ebert MP, Dooley S, Meyer C. Dysregulated paired related homeobox 1 impacts on hepatocellular carcinoma phenotypes. BMC Cancer 2021;21:1006. [PMID: 34496784 DOI: 10.1186/s12885-021-08637-3] [Reference Citation Analysis]
377 Wan J, Liu S, Sun W, Yu H, Tang W, Liu W, Ji J, Liu B. Ring finger protein 152-dependent degradation of TSPAN12 suppresses hepatocellular carcinoma progression.Cancer Cell Int. 2021;21:122. [PMID: 33602225 DOI: 10.1186/s12935-021-01806-1] [Reference Citation Analysis]
378 Lee CM, Lee J, Jang SN, Shon JC, Wu Z, Park K, Liu KH, Park SH. 6,8-Diprenylorobol Induces Apoptosis in Human Hepatocellular Carcinoma Cells via Activation of FOXO3 and Inhibition of CYP2J2. Oxid Med Cell Longev 2020;2020:8887251. [PMID: 33312341 DOI: 10.1155/2020/8887251] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
379 Liu X, Lu Y, Qin S. Atezolizumab and bevacizumab for hepatocellular carcinoma: mechanism, pharmacokinetics and future treatment strategies. Future Oncol 2021;17:2243-56. [PMID: 33663220 DOI: 10.2217/fon-2020-1290] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
380 Tsuchiya A, Ogawa M, Watanabe T, Takeuchi S, Kojima Y, Watanabe Y, Kimura N, Hayashi K, Yokoyama J, Terai S. Diverse perspectives to address for the future treatment of heterogeneous hepatocellular carcinoma. Heliyon 2019;5:e01325. [PMID: 30911692 DOI: 10.1016/j.heliyon.2019.e01325] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
381 Tanaka H, Horioka K, Yamamoto M, Asari M, Okuda K, Yamazaki K, Shimizu K, Ogawa K. Overproduction of thrombopoietin by BRAFV600E-mutated mouse hepatocytes and contribution of thrombopoietin to hepatocarcinogenesis. Cancer Sci 2019;110:2748-59. [PMID: 31301081 DOI: 10.1111/cas.14130] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
382 Philips CA, Rajesh S, Nair DC, Ahamed R, Abduljaleel JK, Augustine P. Hepatocellular Carcinoma in 2021: An Exhaustive Update. Cureus 2021;13:e19274. [PMID: 34754704 DOI: 10.7759/cureus.19274] [Reference Citation Analysis]
383 He GN, Bao NR, Wang S, Xi M, Zhang TH, Chen FS. Ketamine Induces Ferroptosis of Liver Cancer Cells by Targeting lncRNA PVT1/miR-214-3p/GPX4. Drug Des Devel Ther 2021;15:3965-78. [PMID: 34566408 DOI: 10.2147/DDDT.S332847] [Reference Citation Analysis]
384 van Tienderen GS, Groot Koerkamp B, IJzermans JNM, van der Laan LJW, Verstegen MMA. Recreating Tumour Complexity in a Dish: Organoid Models to Study Liver Cancer Cells and their Extracellular Environment. Cancers (Basel). 2019;11. [PMID: 31683901 DOI: 10.3390/cancers11111706] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
385 Kim JH, Joo I, Lee JM. Atypical Appearance of Hepatocellular Carcinoma and Its Mimickers: How to Solve Challenging Cases Using Gadoxetic Acid-Enhanced Liver Magnetic Resonance Imaging. Korean J Radiol 2019;20:1019-41. [PMID: 31270973 DOI: 10.3348/kjr.2018.0636] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
386 Sheng QJ, Tian WY, Dou XG, Zhang C, Li YW, Han C, Fan YX, Lai PP, Ding Y. Programmed death 1, ligand 1 and 2 correlated genes and their association with mutation, immune infiltration and clinical outcomes of hepatocellular carcinoma. World J Gastrointest Oncol 2020; 12(11): 1255-1271 [PMID: 33250959 DOI: 10.4251/wjgo.v12.i11.1255] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
387 Marin JJG, Herraez E, Lozano E, Macias RIR, Briz O. Models for Understanding Resistance to Chemotherapy in Liver Cancer. Cancers (Basel) 2019;11:E1677. [PMID: 31671735 DOI: 10.3390/cancers11111677] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
388 Liang X, Zhou R, Li Y, Yang L, Su M, Lai KP. Clinical characterization and therapeutic targets of vitamin A in patients with hepatocholangiocarcinoma and coronavirus disease. Aging (Albany NY) 2021;13:15785-800. [PMID: 34176789 DOI: 10.18632/aging.203220] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
389 Moreno-Gonzalez M, Beraza N. The Role of the Microbiome in Liver Cancer. Cancers (Basel) 2021;13:2330. [PMID: 34066064 DOI: 10.3390/cancers13102330] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
390 Zhang H, Zhuo C, Zhou D, Zhang M, Zhang F, Chen M, Xu S, Chen Z. Small Nucleolar RNA Host Gene 1 (SNHG1) and Chromosome 2 Open Reading Frame 48 (C2orf48) as Potential Prognostic Signatures for Liver Cancer by Constructing Regulatory Networks. Med Sci Monit 2020;26:e920482. [PMID: 32036380 DOI: 10.12659/MSM.920482] [Reference Citation Analysis]
391 Qu WF, Zhou PY, Liu WR, Tian MX, Jin L, Jiang XF, Wang H, Tao CY, Fang Y, Zhou YF, Song SS, Ding ZB, Peng YF, Dai Z, Qiu SJ, Zhou J, Fan J, Tang Z, Shi YH. Age-adjusted Charlson Comorbidity Index predicts survival in intrahepatic cholangiocarcinoma patients after curative resection. Ann Transl Med 2020;8:487. [PMID: 32395531 DOI: 10.21037/atm.2020.03.23] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
392 Zheng R, Qu C, Zhang S, Zeng H, Sun K, Gu X, Xia C, Yang Z, Li H, Wei W, Chen W, He J. Liver cancer incidence and mortality in China: Temporal trends and projections to 2030. Chin J Cancer Res. 2018;30:571-579. [PMID: 30700925 DOI: 10.21147/j.issn.1000-9604.2018.06.01] [Cited by in Crossref: 62] [Cited by in F6Publishing: 80] [Article Influence: 15.5] [Reference Citation Analysis]
393 Cui YQ, Liu YJ, Zhang F. The suppressive effects of Britannin (Bri) on human liver cancer through inducing apoptosis and autophagy via AMPK activation regulated by ROS. Biochem Biophys Res Commun 2018;497:916-23. [PMID: 29288670 DOI: 10.1016/j.bbrc.2017.12.144] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 4.4] [Reference Citation Analysis]
394 Tian B, Li Q. Single-Cell Sequencing and Its Applications in Liver Cancer. Front Oncol 2022;12:857037. [DOI: 10.3389/fonc.2022.857037] [Reference Citation Analysis]
395 Gowthami J, Gururaj N, Mahalakshmi V, Sathya R, Sabarinath TR, Doss DM. Genetic predisposition and prediction protocol for epithelial neoplasms in disease-free individuals: A systematic review. J Oral Maxillofac Pathol 2020;24:293-307. [PMID: 33456239 DOI: 10.4103/jomfp.JOMFP_348_19] [Reference Citation Analysis]
396 Wang H, Jiang Y, Li B, Cui Y, Li D, Li R. Single-Cell Spatial Analysis of Tumor and Immune Microenvironment on Whole-Slide Image Reveals Hepatocellular Carcinoma Subtypes. Cancers (Basel) 2020;12:E3562. [PMID: 33260561 DOI: 10.3390/cancers12123562] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
397 Lai Y, Feng B, Abudoureyimu M, Zhi Y, Zhou H, Wang T, Chu X, Chen P, Wang R. Non-coding RNAs: Emerging Regulators of Sorafenib Resistance in Hepatocellular Carcinoma. Front Oncol 2019;9:1156. [PMID: 31750247 DOI: 10.3389/fonc.2019.01156] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
398 Feng J, Wu L, Ji J, Chen K, Yu Q, Zhang J, Chen J, Mao Y, Wang F, Dai W, Xu L, Wu J, Guo C. PKM2 is the target of proanthocyanidin B2 during the inhibition of hepatocellular carcinoma. J Exp Clin Cancer Res 2019;38:204. [PMID: 31101057 DOI: 10.1186/s13046-019-1194-z] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 8.0] [Reference Citation Analysis]
399 Zhang Z, Lu M, Qin Y, Gao W, Tao L, Su W, Zhong J. Neoantigen: A New Breakthrough in Tumor Immunotherapy. Front Immunol 2021;12:672356. [PMID: 33936118 DOI: 10.3389/fimmu.2021.672356] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
400 Ziogas DE, Lykoudis EG, Roukos DH, Glantzounis GK. Genomic heterogeneity: next-generation sequencing enables biomarker identification for hepatocellular carcinoma. Biomark Med 2017;11:515-8. [PMID: 28699774 DOI: 10.2217/bmm-2017-0121] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
401 Sun J, Li Y, Wang Y, Liu Y, Liu Y, Wang X. Comparison of anti-HBV regimen with or without adefovir on hepatocellular carcinoma development of Chronic hepatitis B patients with compensated cirrhosis: a retrospective cohort study. Infect Agent Cancer 2018;13:17. [PMID: 29796061 DOI: 10.1186/s13027-018-0189-2] [Reference Citation Analysis]
402 Huang LH, Hsieh TM, Huang CY, Liu YW, Wu SC, Chien PC, Hsieh CH. Disparity of Hepatocellular Carcinoma in Tumor Microenvironment-Related Genes and Infiltrating Immune Cells between Asian and Non-Asian Populations. Genes (Basel) 2021;12:1274. [PMID: 34440448 DOI: 10.3390/genes12081274] [Reference Citation Analysis]
403 Ali ES, Rychkov GY, Barritt GJ. Deranged hepatocyte intracellular Ca2+ homeostasis and the progression of non-alcoholic fatty liver disease to hepatocellular carcinoma. Cell Calcium 2019;82:102057. [PMID: 31401389 DOI: 10.1016/j.ceca.2019.102057] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 6.0] [Reference Citation Analysis]
404 Mansour GH, El-Magd MA, Mahfouz DH, Abdelhamid IA, Mohamed MF, Ibrahim NS, Hady A Abdel Wahab A, Elzayat EM. Bee venom and its active component Melittin synergistically potentiate the anticancer effect of Sorafenib against HepG2 cells. Bioorg Chem 2021;116:105329. [PMID: 34544028 DOI: 10.1016/j.bioorg.2021.105329] [Reference Citation Analysis]
405 Jun SY, Yoon HR, Yoon JY, Jeon SJ, Lee JJ, Halder D, Kim JM, Kim NS. The Human TOR Signaling Regulator Is the Key Indicator of Liver Cancer Patients' Overall Survival: TIPRL/LC3/CD133/CD44 as Potential Biomarkers for Early Liver Cancers. Cancers (Basel) 2021;13:2925. [PMID: 34208132 DOI: 10.3390/cancers13122925] [Reference Citation Analysis]
406 Huang R, Zeng Z, Li G, Song D, Yan P, Yin H, Hu P, Zhu X, Chang R, Zhang X, Zhang J, Meng T, Huang Z. The Construction and Comprehensive Analysis of ceRNA Networks and Tumor-Infiltrating Immune Cells in Bone Metastatic Melanoma. Front Genet 2019;10:828. [PMID: 31608101 DOI: 10.3389/fgene.2019.00828] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
407 Ma X, Zhou L, Zheng S. Transcriptome analysis revealed key prognostic genes and microRNAs in hepatocellular carcinoma. PeerJ 2020;8:e8930. [PMID: 32296612 DOI: 10.7717/peerj.8930] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
408 Bian J, Long J, Yang X, Yang X, Xu Y, Lu X, Guan M, Sang X, Zhao H. Construction and validation of a prognostic signature using CNV-driven genes for hepatocellular carcinoma. Ann Transl Med 2021;9:765. [PMID: 34268378 DOI: 10.21037/atm-20-7101] [Reference Citation Analysis]
409 Zhang Q, Lou Y, Bai XL, Liang TB. Intratumoral heterogeneity of hepatocellular carcinoma: From single-cell to population-based studies. World J Gastroenterol 2020; 26(26): 3720-3736 [PMID: 32774053 DOI: 10.3748/wjg.v26.i26.3720] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
410 Chowdhury MMH, Salazar CJJ, Nurunnabi M. Recent advances in bionanomaterials for liver cancer diagnosis and treatment. Biomater Sci 2021;9:4821-42. [PMID: 34032223 DOI: 10.1039/d1bm00167a] [Reference Citation Analysis]
411 Du W, Chen W, Shu Z, Xiang D, Bi K, Lu Y, Zhang X, Li L, Diao H. Identification of prognostic biomarkers of hepatocellular carcinoma via long noncoding RNA expression and copy number alterations. Epigenomics 2020;12:1303-15. [PMID: 32772564 DOI: 10.2217/epi-2019-0385] [Reference Citation Analysis]
412 Huang TY, Peng SF, Huang YP, Tsai CH, Tsai FJ, Huang CY, Tang CH, Yang JS, Hsu YM, Yin MC, Huang WW, Chung JG. Combinational treatment of all-trans retinoic acid (ATRA) and bisdemethoxycurcumin (BDMC)-induced apoptosis in liver cancer Hep3B cells. J Food Biochem 2020;44:e13122. [PMID: 31837044 DOI: 10.1111/jfbc.13122] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
413 Sun X, Hou Z, Li N, Zhang S. MiR-597-5p suppresses the progression of hepatocellular carcinoma via targeting transcriptional enhancer associate domain transcription factor 1 (TEAD1). In Vitro Cell Dev Biol Anim 2022. [PMID: 35169903 DOI: 10.1007/s11626-021-00614-1] [Reference Citation Analysis]
414 Lee YA, Noon LA, Akat KM, Ybanez MD, Lee TF, Berres ML, Fujiwara N, Goossens N, Chou HI, Parvin-Nejad FP, Khambu B, Kramer EGM, Gordon R, Pfleger C, Germain D, John GR, Campbell KN, Yue Z, Yin XM, Cuervo AM, Czaja MJ, Fiel MI, Hoshida Y, Friedman SL. Autophagy is a gatekeeper of hepatic differentiation and carcinogenesis by controlling the degradation of Yap. Nat Commun 2018;9:4962. [PMID: 30470740 DOI: 10.1038/s41467-018-07338-z] [Cited by in Crossref: 48] [Cited by in F6Publishing: 54] [Article Influence: 12.0] [Reference Citation Analysis]
415 Yao J, Fu J, Liu Y, Qu W, Wang G, Yan Z. LncRNA CASC9 promotes proliferation, migration and inhibits apoptosis of hepatocellular carcinoma cells by down-regulating miR-424-5p. Ann Hepatol 2021;23:100297. [PMID: 33346094 DOI: 10.1016/j.aohep.2020.100297] [Reference Citation Analysis]
416 Gu ZL, Huang J, Zhen LL. Knockdown of otubain 2 inhibits liver cancer cell growth by suppressing NF-κB signaling. Kaohsiung J Med Sci 2020;36:399-404. [PMID: 32003539 DOI: 10.1002/kjm2.12187] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
417 Zhang Y, Wang H, Xiao H. Metformin Actions on the Liver: Protection Mechanisms Emerging in Hepatocytes and Immune Cells against NASH-Related HCC. Int J Mol Sci 2021;22:5016. [PMID: 34065108 DOI: 10.3390/ijms22095016] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
418 Lei X, Zhang M, Guan B, Chen Q, Dong Z, Wang C. Identification of hub genes associated with prognosis, diagnosis, immune infiltration and therapeutic drug in liver cancer by integrated analysis. Hum Genomics 2021;15:39. [PMID: 34187556 DOI: 10.1186/s40246-021-00341-4] [Reference Citation Analysis]
419 Ramos IPR, Dias ML, Nunes De Moraes AC, Meireles Ferreira FG, Souza SAL, Gutfilen B, Barboza T, Ferreira Pimentel C, Paz Batista CM, Kasai-Brunswick TH, Fortes FDSA, De Andrade CBV, Goldenberg RCDS. Granulocyte Colony-Stimulating Factor Treatment Before Radiotherapy Protects Against Radiation-Induced Liver Disease in Mice. Front Pharmacol 2021;12:725084. [PMID: 34867327 DOI: 10.3389/fphar.2021.725084] [Reference Citation Analysis]
420 Deng T, Li J, He B, Chen B, Liu F, Chen Z, Zheng J, Shi Z, Zhang T, Deng L, Yu H, Yang J, Wu L, Shan Y, Yu Z, Chen X, Wang Y, Chen G. Gut microbiome alteration as a diagnostic tool and associated with inflammatory response marker in primary liver cancer. Hepatol Int. [DOI: 10.1007/s12072-021-10279-3] [Reference Citation Analysis]
421 Zong J, Peng H, Qing X, Fan Z, Xu W, Du X, Shi R, Zhang Y. pH-Responsive Pluronic F127-Lenvatinib-Encapsulated Halogenated Boron-Dipyrromethene Nanoparticles for Combined Photodynamic Therapy and Chemotherapy of Liver Cancer. ACS Omega 2021;6:12331-42. [PMID: 34056385 DOI: 10.1021/acsomega.1c01346] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
422 Sun C, Huang S, Ju W, Hou Y, Wang Z, Liu Y, Wu L, He X. Elevated DSN1 expression is associated with poor survival in patients with hepatocellular carcinoma. Hum Pathol 2018;81:113-20. [PMID: 30136646 DOI: 10.1016/j.humpath.2018.06.032] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
423 Rodríguez MM, Fiore E, Bayo J, Atorrasagasti C, García M, Onorato A, Domínguez L, Malvicini M, Mazzolini G. 4Mu Decreases CD47 Expression on Hepatic Cancer Stem Cells and Primes a Potent Antitumor T Cell Response Induced by Interleukin-12. Mol Ther 2018;26:2738-50. [PMID: 30301668 DOI: 10.1016/j.ymthe.2018.09.012] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 4.8] [Reference Citation Analysis]
424 Shiota J, Samuelson LC, Razumilava N. Hepatobiliary Organoids and Their Applications for Studies of Liver Health and Disease: Are We There Yet? Hepatology 2021. [PMID: 33638203 DOI: 10.1002/hep.31772] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
425 Zhang J, Huang J, Chen W, Hu Z, Wang X. miR-143-3p Targets lncRNA PSMG3-AS1 to Inhibit the Proliferation of Hepatocellular Carcinoma Cells. Cancer Manag Res 2020;12:6303-9. [PMID: 32801875 DOI: 10.2147/CMAR.S242179] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
426 Ben-moshe S, Itzkovitz S. Spatial heterogeneity in the mammalian liver. Nat Rev Gastroenterol Hepatol 2019;16:395-410. [DOI: 10.1038/s41575-019-0134-x] [Cited by in Crossref: 71] [Cited by in F6Publishing: 61] [Article Influence: 23.7] [Reference Citation Analysis]
427 Liang L, Huan L, Wang J, Wu Y, Huang S, He X. LncRNA RP11-295G20.2 regulates hepatocellular carcinoma cell growth and autophagy by targeting PTEN to lysosomal degradation. Cell Discov 2021;7:118. [PMID: 34903728 DOI: 10.1038/s41421-021-00339-1] [Reference Citation Analysis]
428 Chen W, Bi K, Zhang X, Jiang J, Diao H. In-depth characterization of the biomarkers based on tumor-infiltrated immune cells reveals implications for diagnosis and prognosis in hepatocellular carcinoma. J Transl Autoimmun 2020;3:100067. [PMID: 33073226 DOI: 10.1016/j.jtauto.2020.100067] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
429 Ma Y, Cao, Li G, Hu J, Liu X, Liu J. Silence of lncRNA HEIH suppressed liver cancer cell growth and metastasis through miR-199a-3p/mTOR axis. J Cell Biochem 2019;120:17757-66. [PMID: 31144384 DOI: 10.1002/jcb.29041] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
430 Hin Tang JJ, Hao Thng DK, Lim JJ, Toh TB. JAK/STAT signaling in hepatocellular carcinoma. Hepat Oncol 2020;7:HEP18. [PMID: 32273976 DOI: 10.2217/hep-2020-0001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
431 Alhakamy NA, Ahmed OAA, Aldawsari HM, Alfaifi MY, Eid BG, Abdel-Naim AB, Fahmy UA. Encapsulation of Lovastatin in Zein Nanoparticles Exhibits Enhanced Apoptotic Activity in HepG2 Cells. Int J Mol Sci 2019;20:E5788. [PMID: 31752085 DOI: 10.3390/ijms20225788] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
432 Zheng Y, Wang S, Cai J, Ke A, Fan J. The progress of immune checkpoint therapy in primary liver cancer. Biochim Biophys Acta Rev Cancer 2021;1876:188638. [PMID: 34688805 DOI: 10.1016/j.bbcan.2021.188638] [Reference Citation Analysis]
433 Guedj N, Blaise L, Cauchy F, Albuquerque M, Soubrane O, Paradis V. Prognostic value of desmoplastic stroma in intrahepatic cholangiocarcinoma. Mod Pathol 2021;34:408-16. [PMID: 32860001 DOI: 10.1038/s41379-020-00656-y] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
434 Mooring M, Fowl BH, Lum SZC, Liu Y, Yao K, Softic S, Kirchner R, Bernstein A, Singhi AD, Jay DG, Kahn CR, Camargo FD, Yimlamai D. Hepatocyte Stress Increases Expression of Yes-Associated Protein and Transcriptional Coactivator With PDZ-Binding Motif in Hepatocytes to Promote Parenchymal Inflammation and Fibrosis. Hepatology 2020;71:1813-30. [PMID: 31505040 DOI: 10.1002/hep.30928] [Cited by in Crossref: 22] [Cited by in F6Publishing: 28] [Article Influence: 11.0] [Reference Citation Analysis]
435 Correia de Sousa M, Calo N, Sobolewski C, Gjorgjieva M, Clément S, Maeder C, Dolicka D, Fournier M, Vinet L, Montet X, Dufour JF, Humar B, Negro F, Sempoux C, Foti M. Mir-21 Suppression Promotes Mouse Hepatocarcinogenesis. Cancers (Basel) 2021;13:4983. [PMID: 34638467 DOI: 10.3390/cancers13194983] [Reference Citation Analysis]
436 Berman ZT, Newton I. Diagnosis, Staging, and Patient Selection for Locoregional Therapy to Treat Hepatocellular Carcinoma. Semin Intervent Radiol 2020;37:441-7. [PMID: 33328699 DOI: 10.1055/s-0040-1719185] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
437 Huang S, Li J, Tam NL, Sun C, Hou Y, Hughes B, Wang Z, Zhou Q, He X, Wu L. Uridine-cytidine kinase 2 upregulation predicts poor prognosis of hepatocellular carcinoma and is associated with cancer aggressiveness. Mol Carcinog 2019;58:603-15. [PMID: 30556610 DOI: 10.1002/mc.22954] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
438 Katoh M. Fibroblast growth factor receptors as treatment targets in clinical oncology. Nat Rev Clin Oncol 2019;16:105-22. [DOI: 10.1038/s41571-018-0115-y] [Cited by in Crossref: 86] [Cited by in F6Publishing: 86] [Article Influence: 21.5] [Reference Citation Analysis]
439 Lv R, Tian Y, Yu Z, Liu C. Clinical efficacy of computed tomography-guided microwave ablation sequential transcatheter arterial chemoembolization under edge calculation for primary liver cancer over 5 cm in diameter. J Supercomput. [DOI: 10.1007/s11227-021-04118-3] [Reference Citation Analysis]
440 Wu Y, Liu Z, Xu X. Molecular subtyping of hepatocellular carcinoma: A step toward precision medicine. Cancer Commun (Lond) 2020;40:681-93. [PMID: 33290597 DOI: 10.1002/cac2.12115] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
441 Ge Z, Ma J, Qiao B, Wang Y, Zhang H, Gou W. Impact of tenofovir antiviral treatment on survival of chronic hepatitis B related hepatocellular carcinoma after hepatectomy in Chinese individuals from Qingdao municipality. Medicine (Baltimore) 2020;99:e21454. [PMID: 32769872 DOI: 10.1097/MD.0000000000021454] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
442 Wang XY, Zhu WW, Wang Z, Huang JB, Wang SH, Bai FM, Li TE, Zhu Y, Zhao J, Yang X, Lu L, Zhang JB, Jia HL, Dong QZ, Chen JH, Andersen JB, Ye D, Qin LX. Driver mutations of intrahepatic cholangiocarcinoma shape clinically relevant genomic clusters with distinct molecular features and therapeutic vulnerabilities. Theranostics 2022;12:260-76. [PMID: 34987644 DOI: 10.7150/thno.63417] [Reference Citation Analysis]
443 Chu YW, Chien CH, Sung MI, Chen CW, Chen YT. dBMHCC: A comprehensive hepatocellular carcinoma (HCC) biomarker database provides a reliable prediction system for novel HCC phosphorylated biomarkers. PLoS One 2020;15:e0234084. [PMID: 32497121 DOI: 10.1371/journal.pone.0234084] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
444 Köhler BC, Waldburger N, Schlamp K, Jäger D, Weiss KH, Schulze-Bergkamen H, Schirmacher P, Springfeld C. Liver cancers with stem/progenitor-cell features - a rare chemotherapy-sensitive malignancy. Oncotarget 2017;8:59991-8. [PMID: 28938700 DOI: 10.18632/oncotarget.19000] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
445 Liang L, Zhu K, Tao J, Lu S. ORN: Inferring patient-specific dysregulation status of pathway modules in cancer with OR-gate Network. PLoS Comput Biol 2021;17:e1008792. [PMID: 33819263 DOI: 10.1371/journal.pcbi.1008792] [Reference Citation Analysis]
446 Bondoc A, Glaser K, Jin K, Lake C, Cairo S, Geller J, Tiao G, Aronow B. Identification of distinct tumor cell populations and key genetic mechanisms through single cell sequencing in hepatoblastoma. Commun Biol 2021;4:1049. [PMID: 34497364 DOI: 10.1038/s42003-021-02562-8] [Reference Citation Analysis]
447 Li K, Chen Y. CYP2C8 regulated by GAS5/miR-382-3p exerts anti-cancerous properties in liver cancer. Cancer Biol Ther 2020;21:1145-53. [PMID: 33180658 DOI: 10.1080/15384047.2020.1840886] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
448 Ahmad M, Dhasmana A, Harne PS, Zamir A, Hafeez BB. Chemokine Clouding and Liver Cancer Heterogeneity: Does it Impact Clinical Outcomes? Seminars in Cancer Biology 2022. [DOI: 10.1016/j.semcancer.2022.02.015] [Reference Citation Analysis]
449 Han Z, Zhao X, Zhang E, Ma J, Zhang H, Li J, Xie W, Li X. Resistomycin Induced Apoptosis and Cycle Arrest in Human Hepatocellular Carcinoma Cells by Activating p38 MAPK Pathway In Vitro and In Vivo. Pharmaceuticals (Basel) 2021;14:958. [PMID: 34681182 DOI: 10.3390/ph14100958] [Reference Citation Analysis]
450 Mora MI, Molina M, Odriozola L, Elortza F, Mato JM, Sitek B, Zhang P, He F, Latasa MU, Ávila MA, Corrales FJ. Prioritizing Popular Proteins in Liver Cancer: Remodelling One-Carbon Metabolism. J Proteome Res 2017;16:4506-14. [PMID: 28944671 DOI: 10.1021/acs.jproteome.7b00390] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
451 Jędrzak A, Grześkowiak BF, Golba K, Coy E, Synoradzki K, Jurga S, Jesionowski T, Mrówczyński R. Magnetite Nanoparticles and Spheres for Chemo- and Photothermal Therapy of Hepatocellular Carcinoma in vitro. Int J Nanomedicine 2020;15:7923-36. [PMID: 33116509 DOI: 10.2147/IJN.S257142] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
452 Wang G, Yan M, Hao R, Lv P, Wang Y, Man S, Gao W. Q-marker identification of Paris polyphylla var. yunnanensis (Franch.) Hand.-Mazz. in pulmonary metastasis of liver cancer mice. J Ethnopharmacol 2022;293:115311. [PMID: 35461989 DOI: 10.1016/j.jep.2022.115311] [Reference Citation Analysis]
453 Feng J, Li J, Wu L, Yu Q, Ji J, Wu J, Dai W, Guo C. Emerging roles and the regulation of aerobic glycolysis in hepatocellular carcinoma. J Exp Clin Cancer Res 2020;39:126. [PMID: 32631382 DOI: 10.1186/s13046-020-01629-4] [Cited by in Crossref: 23] [Cited by in F6Publishing: 30] [Article Influence: 11.5] [Reference Citation Analysis]
454 Sun Y, Sun H. Retracted :Propofol exerts anticancer activity on hepatocellular carcinoma cells by raising lncRNA DGCR5. J Cell Physiol 2020;235:2963-72. [DOI: 10.1002/jcp.29202] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
455 Xie F, Feng S, Yang H, Mao Y. Extracellular vesicles in hepatocellular cancer and cholangiocarcinoma. Ann Transl Med 2019;7:86. [PMID: 31019936 DOI: 10.21037/atm.2019.01.12] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
456 Tang Y, Zhang Y, Liu S, Sun Z, Wang C, Li L, Zhou W, Cheng S. 14-3-3ζ binds to and stabilizes phospho-beclin 1S295 and induces autophagy in hepatocellular carcinoma cells. J Cell Mol Med 2020;24:954-64. [PMID: 31709727 DOI: 10.1111/jcmm.14806] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
457 Olya M, Zaferani Arani H, Shekarriz A, Zabolian A, Zare Marzouni H, Aryan H, Hoseinian M, Javidi MA, Atashi HA. Hypericin Exerts Detrimental Effect on Huh-7 As a Delegacy of Hepatocellular Carcinoma: A P53 Dependent Pathway. Galen Med J 2020;9:e1896. [PMID: 34466606 DOI: 10.31661/gmj.v9i0.1896] [Reference Citation Analysis]